<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1" specific-use="sps-1.9" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
	<front>
		<journal-meta>
			<journal-id journal-id-type="nlm-ta">Rev Saude Publica</journal-id>
			<journal-id journal-id-type="publisher-id">rsp</journal-id>
			<journal-title-group>
				<journal-title>Revista de Saúde Pública</journal-title>
				<abbrev-journal-title abbrev-type="publisher">Rev. Saúde Pública</abbrev-journal-title>
			</journal-title-group>
			<issn pub-type="ppub">0034-8910</issn>
			<issn pub-type="epub">1518-8787</issn>
			<publisher>
				<publisher-name>Faculdade de Saúde Pública da Universidade de São Paulo</publisher-name>
			</publisher>
		</journal-meta>
		<article-meta>
			<article-id pub-id-type="other">00208</article-id>
			<article-id pub-id-type="doi">10.11606/s1518-8787.2022056003740</article-id>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>Original Article</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Benzodiazepines utilization in Brazilian older adults: a population-based study</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-9307-4337</contrib-id>
					<name>
						<surname>Freire</surname>
						<given-names>Marina de Borba Oliveira</given-names>
					</name>
					<xref ref-type="aff" rid="aff1"><sup>I</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-2917-7320</contrib-id>
					<name>
						<surname>Da Silva</surname>
						<given-names>Bruna Gonçalves Cordeiro</given-names>
					</name>
					<xref ref-type="aff" rid="aff2"><sup>II</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-4680-3197</contrib-id>
					<name>
						<surname>Bertoldi</surname>
						<given-names>Andréa Dâmaso</given-names>
					</name>
					<xref ref-type="aff" rid="aff2"><sup>II</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-0455-9429</contrib-id>
					<name>
						<surname>Fontanella</surname>
						<given-names>Andréia Turmina</given-names>
					</name>
					<xref ref-type="aff" rid="aff3"><sup>III</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-3349-8541</contrib-id>
					<name>
						<surname>Mengue</surname>
						<given-names>Sotero Serrate</given-names>
					</name>
					<xref ref-type="aff" rid="aff3"><sup>III</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-3143-8315</contrib-id>
					<name>
						<surname>Ramos</surname>
						<given-names>Luiz Roberto</given-names>
					</name>
					<xref ref-type="aff" rid="aff4"><sup>IV</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-6180-7527</contrib-id>
					<name>
						<surname>Tavares</surname>
						<given-names>Noemia Urruth Leão</given-names>
					</name>
					<xref ref-type="aff" rid="aff5"><sup>V</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-7566-7745</contrib-id>
					<name>
						<surname>Pizzol</surname>
						<given-names>Tatiane da Silva Dal</given-names>
					</name>
					<xref ref-type="aff" rid="aff6"><sup>VI</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-4502-8467</contrib-id>
					<name>
						<surname>Arrais</surname>
						<given-names>Paulo Sérgio Dourado</given-names>
					</name>
					<xref ref-type="aff" rid="aff7"><sup>VII</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-4319-9318</contrib-id>
					<name>
						<surname>Farias</surname>
						<given-names>Mareni Rocha</given-names>
					</name>
					<xref ref-type="aff" rid="aff8"><sup>VIII</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-6245-7522</contrib-id>
					<name>
						<surname>Luiza</surname>
						<given-names>Vera Lucia</given-names>
					</name>
					<xref ref-type="aff" rid="aff9"><sup>IX</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-2400-536X</contrib-id>
					<name>
						<surname>Oliveira</surname>
						<given-names>Maria Auxiliadora</given-names>
					</name>
					<xref ref-type="aff" rid="aff9"><sup>IX</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-2996-9427</contrib-id>
					<name>
						<surname>Menezes</surname>
						<given-names>Ana Maria Baptista</given-names>
					</name>
					<xref ref-type="aff" rid="aff2"><sup>II</sup></xref>
				</contrib>
			</contrib-group>
			<aff id="aff1">
				<label>I</label>
				<institution content-type="orgname">Universidade Federal de Pelotas</institution>
				<institution content-type="orgdiv1">Faculdade de Medicina</institution>
				<institution content-type="orgdiv2">Programa de Pós-Graduação em Epidemiologia</institution>
				<addr-line>
					<named-content content-type="city">Pelotas</named-content>
					<named-content content-type="state">RS</named-content>
				</addr-line>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Universidade Federal de Pelotas . Faculdade de Medicina . Programa de Pós-Graduação em Epidemiologia . Pelotas , RS , Brasil </institution>
			</aff>
			<aff id="aff2">
				<label>II</label>
				<institution content-type="orgname">Universidade Federal de Pelotas</institution>
				<institution content-type="orgdiv1">Faculdade de Medicina</institution>
				<institution content-type="orgdiv2">Departamento de Medicina Social</institution>
				<addr-line>
					<named-content content-type="city">Pelotas</named-content>
					<named-content content-type="state">RS</named-content>
				</addr-line>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Universidade Federal de Pelotas . Faculdade de Medicina . Departamento de Medicina Social . Pelotas , RS , Brasil </institution>
			</aff>
			<aff id="aff3">
				<label>III</label>
				<institution content-type="orgname">Universidade Federal do Rio Grande do Sul</institution>
				<institution content-type="orgdiv1">Faculdade de Medicina</institution>
				<institution content-type="orgdiv2">Programa de Pós-Graduação em Epidemiologia</institution>
				<addr-line>
					<named-content content-type="city">Porto Alegre</named-content>
					<named-content content-type="state">RS</named-content>
				</addr-line>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Universidade Federal do Rio Grande do Sul . Faculdade de Medicina . Programa de Pós-Graduação em Epidemiologia . Porto Alegre , RS , Brasil </institution>
			</aff>
			<aff id="aff4">
				<label>IV</label>
				<institution content-type="orgname">Universidade Federal de São Paulo</institution>
				<institution content-type="orgdiv1">Escola Paulista de Medicina</institution>
				<institution content-type="orgdiv2">Departamento de Medicina Preventiva</institution>
				<addr-line>
					<named-content content-type="city">São Paulo</named-content>
					<named-content content-type="state">SP</named-content>
				</addr-line>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Universidade Federal de São Paulo . Escola Paulista de Medicina . Departamento de Medicina Preventiva . São Paulo , SP , Brasil </institution>
			</aff>
			<aff id="aff5">
				<label>V</label>
				<institution content-type="orgname">Universidade de Brasília</institution>
				<institution content-type="orgdiv1">Faculdade de Ciências da Saúde</institution>
				<institution content-type="orgdiv2">Departamento de Farmácia</institution>
				<addr-line>
					<named-content content-type="city">Brasília</named-content>
					<named-content content-type="state">DF</named-content>
				</addr-line>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Universidade de Brasília . Faculdade de Ciências da Saúde . Departamento de Farmácia . Brasília , DF , Brasil </institution>
			</aff>
			<aff id="aff6">
				<label>VI</label>
				<institution content-type="orgname">Universidade Federal do Rio Grande do Sul</institution>
				<institution content-type="orgdiv1">Faculdade de Farmácia</institution>
				<institution content-type="orgdiv2">Departamento de Produção e Controle de Medicamentos</institution>
				<addr-line>
					<named-content content-type="city">Porto Alegre</named-content>
					<named-content content-type="state">RS</named-content>
				</addr-line>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Universidade Federal do Rio Grande do Sul . Faculdade de Farmácia . Departamento de Produção e Controle de Medicamentos . Porto Alegre , RS , Brasil </institution>
			</aff>
			<aff id="aff7">
				<label>VII</label>
				<institution content-type="orgname">Universidade Federal do Ceará</institution>
				<institution content-type="orgdiv1">Faculdade de Farmácia, Odontologia e Enfermagem</institution>
				<institution content-type="orgdiv2">Departamento de Farmácia</institution>
				<addr-line>
					<named-content content-type="city">Fortaleza</named-content>
					<named-content content-type="state">CE</named-content>
				</addr-line>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Universidade Federal do Ceará . Faculdade de Farmácia, Odontologia e Enfermagem . Departamento de Farmácia . Fortaleza , CE , Brasil </institution>
			</aff>
			<aff id="aff8">
				<label>VIII</label>
				<institution content-type="orgname">Universidade Federal de Santa Catarina</institution>
				<institution content-type="orgdiv1">Centro de Ciências da Saúde</institution>
				<institution content-type="orgdiv2">Departamento de Ciências Farmacêuticas</institution>
				<addr-line>
					<named-content content-type="city">Florianópolis</named-content>
					<named-content content-type="state">SC</named-content>
				</addr-line>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Universidade Federal de Santa Catarina . Centro de Ciências da Saúde . Departamento de Ciências Farmacêuticas . Florianópolis , SC , Brasil </institution>
			</aff>
			<aff id="aff9">
				<label> IX </label>
				<institution content-type="orgname">Fundação Oswaldo Cruz</institution>
				<institution content-type="orgdiv1">Escola Nacional de Saúde Pública Sergio Arouca</institution>
				<institution content-type="orgdiv2">Departamento de Política de Medicamentos e Assistência Farmacêutica</institution>
				<addr-line>
					<named-content content-type="city">Rio de Janeiro</named-content>
					<named-content content-type="state">RJ</named-content>
				</addr-line>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Fundação Oswaldo Cruz . Escola Nacional de Saúde Pública Sergio Arouca . Departamento de Política de Medicamentos e Assistência Farmacêutica . Rio de Janeiro , RJ , Brasil </institution>
			</aff>
			<author-notes>
				<corresp id="c01">Correspondence: Marina de Borba Oliveira Freire Rua Marechal Deodoro, 1.160 96020-220 Pelotas, RS, Brasil E-mail: <email>deborbamarina@gmail.com</email>
				</corresp>
				<fn fn-type="con">
					<p><bold>Authors’ Contribution:</bold> Study design and planning: MBOF, BGCS, ADB, AMBM. Data analysis and interpretation: MBOF, BGCS, ADB, AMBM. Elaboration or revision of the manuscript: MBOF, BGCS, ADB, ATF, SSM, LRR, NULT, TSDP, PSDA, MRF, VLL, MAO, AMBM. Final version approval: MBOF, BGCS, ADB, ATF, SSM, LRR, NULT, TSDP, PSDA, MRF, VLL, MAO, AMBM.. Public responsibility for this content: MBOF, BGCS, ADB, ATF, SSM, LRR, NULT, TSDP, PSDA, MRF, VLL, MAO, AMBM.</p>
				</fn>
				<fn fn-type="conflict">
					<p><bold>Conflict of Interest:</bold> The authors declare no conflicts of interest.</p>
				</fn>
			</author-notes>
			<pub-date date-type="pub" publication-format="electronic">
				<day>21</day>
				<month>03</month>
				<year>2022</year>
			</pub-date>
			<pub-date date-type="collection" publication-format="electronic">
				<year>2022</year>
			</pub-date>
			<volume>56</volume>
			<elocation-id>10</elocation-id>
			<history>
				<date date-type="received">
					<day>12</day>
					<month>04</month>
					<year>2021</year>
				</date>
				<date date-type="accepted">
					<day>4</day>
					<month>06</month>
					<year>2021</year>
				</date>
			</history>
			<permissions>
				<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="en">
					<license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
				</license>
			</permissions>
			<abstract>
				<title>ABSTRACT</title>
				<sec>
					<title>OBJECTIVE</title>
					<p>To evaluate the utilization of benzodiazepines (BZD) in Brazilian older adults, based on the <italic>Pesquisa Nacional de Acesso, Utilização e Promoção do Uso Racional de Medicamentos</italic> (PNAUM - National Survey of Access, Use and Promotion of Rational Use of Medicines).</p>
				</sec>
				<sec>
					<title>METHODS</title>
					<p>The PNAUM is a cross-sectional study conducted between 2013 and 2014, representing the Brazilian urban population. In the present study, we included 60 years or older (n = 9,019) individuals. We calculated the prevalence of BZD utilization in the 15 days prior to survey data collection according to independent variables, using a hierarchical Poisson regression model. A semistructured interview performed empirical data collection (household interview).</p>
				</sec>
				<sec>
					<title>RESULTS</title>
					<p>The prevalence of BZD utilization in the older adults was 9.3% (95%CI: 8.3–10.4). After adjustments, BZD utilization was associated with female sex (PR = 1.88; 95%CI: 1.52–2.32), depression (PR = 5.31; 95%CI: 4.41–6, 38), multimorbidity (PR = 1.44; 95%CI: 1.20–1.73), emergency room visit or hospitalization in the last 12 months (PR = 1.42; 95%CI: 1.18–1.70 ), polypharmacy (PR = 1.26; 95%CI: 1.01–1.57) and poor or very poor self-rated health (PR = 4.16; 95%CI: 2.10–8.22). Utilization was lower in the North region (PR = 0.18; 95%CI: 0.13–0.27) and in individuals who reported abusive alcohol consumption in the last month (PR = 0.42; 95%CI: 0.19–0.94).</p>
				</sec>
				<sec>
					<title>CONCLUSION</title>
					<p>Despite contraindications, results showed a high prevalence of BZD utilization in older adults, particularly in those with depression, and wide regional and sex differences.</p>
				</sec>
			</abstract>
			<kwd-group xml:lang="en">
				<kwd>Aged</kwd>
				<kwd>Drug Utilization</kwd>
				<kwd>Benzodiazepines</kwd>
				<kwd>Risk Factors</kwd>
				<kwd>Cross-Sectional Studies</kwd>
			</kwd-group>
			<funding-group>
				<award-group>
					<funding-source>Ministry of Health</funding-source>
					<award-id>25000.111834/2</award-id>
				</award-group>
				<funding-statement>Funding: Secretaria de Ciência e Tecnologia Insumos Estratégicos (SCTIE - Secretariat of Science and Technology Strategic Inputs) on behalf of the Ministry of Health (Process 25000.111834/2).</funding-statement>
			</funding-group>
			<counts>
				<fig-count count="6"/>
				<table-count count="4"/>
				<equation-count count="0"/>
				<ref-count count="30"/>
			</counts>
		</article-meta>
	</front>
	<body>
		<sec sec-type="intro">
			<title>INTRODUCTION</title>
			<p>The first benzodiazepines (BZDs) were synthesized in the 1950s and <sup><xref ref-type="bibr" rid="B1">1</xref></sup> achieved great popularity in the following years due to their proven efficacy in the treatment of anxiety, insomnia, aggression and seizures <sup><xref ref-type="bibr" rid="B2">2</xref></sup> , in addition to adjuvant utilization in other clinical conditions, such as muscle relaxation and analgesia <sup><xref ref-type="bibr" rid="B3">3</xref></sup> . The low incidence of respiratory depression with BZDs taken orally provided a sense of security and contributed to making the class one of the most prescribed around the world <sup><xref ref-type="bibr" rid="B2">2</xref></sup> .</p>
			<p>However, prolonged utilization was associated with a wide range of adverse events and weak evidence of long-term benefit <sup><xref ref-type="bibr" rid="B4">4</xref></sup> . Adverse events documented on BZDs utilization include dementia, cognitive decline, psychomotor disorders, daytime sleepiness, car accidents, tolerance, and dependence <sup><xref ref-type="bibr" rid="B3">3</xref></sup> , besides a higher incidence of fractures and falls, mobility restriction, and reduced social participation in the older adults <sup><xref ref-type="bibr" rid="B5">5</xref></sup> . Therefore, BZDs are classified as potentially inappropriate drugs, whose prescription should be avoided in older adults <sup><xref ref-type="bibr" rid="B6">6</xref></sup> . However, despite this recommendation, the literature points out an increase in BZDs utilization along ageing <sup><xref ref-type="bibr" rid="B7">7</xref></sup> , despite the higher risk of adverse events associated with changes in pharmacodynamics and pharmacokinetics induced by age and polypharmacy <sup><xref ref-type="bibr" rid="B8">8</xref></sup> .</p>
			<p>In this scenario, the <italic>Comitê Nacional para a Promoção do Uso Racional de Medicamentos</italic> (National Committee for the Promotion of the Rational Use of Medicines), on behalf of the Ministry of Health, launched the “ <italic>Uso de Medicamentos e Medicalização da Vida: Recomendações e Estratégias</italic> ” (“Drug utilization and Medicalization of Life: Recommendations and Strategies”) in 2019, prompting the rational utilization of medicines by encouraging education, information, regulation, and research. The publication highlighted the need to restrict the prescription of BZD to individuals aged 60 years and over <sup><xref ref-type="bibr" rid="B9">9</xref></sup> .</p>
			<p>So far, no studies with national representation evaluated BZD utilization in older adults. The present study aims to fill this gap in the literature, evaluating the prevalence of BZD utilization in Brazilian older adults and its distribution according to sociodemographic, behavioral, and health-related variables based on data from the <italic>Pesquisa Nacional de Acesso, Utilização e Promoção do Uso Racional de Medicamentos</italic> (PNAUM - National Research on Access, Use and Promotion of Rational Use of Medicines).</p>
		</sec>
		<sec sec-type="methods">
			<title>METHODS</title>
			<p>The PNAUM was a cross-sectional, population-based study conducted between September 2013 and February 2014, which included individuals of all ages, living in urban areas of the Brazilian territory (n = 41,433). The sampling process was carried out in three stages (municipalities, census tracts and households), followed by a post-stratification process by region, sex, and age, ensuring the representativeness of the Brazilian population. Data collection was carried out through a face-to-face household interview, with data recording on a tablet using specific software for the survey questionnaires. Information on respondents unable to communicate was obtained by a surrogate informant. Additional information is available elsewhere <sup><xref ref-type="bibr" rid="B10">10</xref></sup> .</p>
			<p>In the present study, we analyzed data referring to older adults (60 years and over) interviewed in the survey (n = 9,019).</p>
			<p>The dependent variable analyzed was the BZD utilization in the 15 days prior to the collection of the research data, constructed with information from two investigated variables: 1) chronic medication utilization, in which all medications referred to by the interviewee as being in current use were evaluated for the treatment of a certain chronic disease; and 2) medications for occasional use, based on the following question: “In the last 15 days, have you taken any medication for sleeping or for nerves?”. When the answer was positive, an additional question was asked: “How long will the treatment last?” (taken only once; until improvement/cure; will not take it anymore; whenever symptoms return; forever).</p>
			<p>In order to ensure a better quality of information, the interviewee was asked to show the box(es) or prescription(s) of the medication(s).</p>
			<p>BZDs were considered to be a medication classified according to the <italic>Anatomical Therapeutic Chemical Index</italic> (ATC Index), developed by the <italic>World Health Organization Collaboration Center for Drugs</italic>
 <sup><xref ref-type="bibr" rid="B11">11</xref></sup> Statistic Methodology, under the codes N05BA (anxiolytic BZD derivatives) and N05CD (hypnotic BZD derivatives) in Brazil, in addition to clonazepam, classified as an anticonvulsant under code N03AE01. Information was also collected on the use of medications related to BZDs marketed in Brazil (zolpidem and zopiclone), under code N05CF <sup><xref ref-type="bibr" rid="B11">11</xref></sup> , although these drugs were not included in the main outcome because they do not belong to the BZD class.</p>
			<p>The independent variables encompassed sociodemographic, behavioral and health-related factors:</p>
			<p>a.Sociodemographic: region (North; Northeast; Midwest; Southeast; South); sex (male; female); age (years: 60 to 69; 70 to 79; 80 or older); self-reported skin color (white; black; mixed; yellow; Indigenous); marital status (without a partner; with a partner); schooling (years of study: 0 to 4; 5 to 8; 9 to 11; 12 or more); socioeconomic level (AB [richest]; C; D; E [poorest]), according to the classification of the <italic>Associação Brasileira de Empresas de Pesquisa</italic> (ABEP - Brazilian Association of Research Companies) <sup><xref ref-type="bibr" rid="B12">12</xref></sup> ;</p>
			<p>b.Behavioral: smoking (current smoker; former smoker; non-smoker); abusive consumption of alcohol in the last month (yes; no), defined as abusive consumption of four or more doses of alcoholic beverage (woman) or five or more doses (man), on a single occasion, at least once in the last month. By “dose”, we understand an alcoholic beverage equivalent to a can of beer, a glass of wine or a dose of liquor ( <italic>cachaça</italic> ), whiskey or any other distilled alcoholic beverage;</p>
			<p>c.Health-related: health insurance (yes; no); depression (yes; no), assessed through the question: “Has a doctor ever told you that you have depression?”; multimorbidity (yes; no), considering the presence of two or more chronic diseases as multimorbidity. Diseases included: high blood pressure, diabetes, heart disease, high cholesterol, ischemia or stroke, asthma, chronic obstructive pulmonary disease (emphysema or chronic bronchitis), and rheumatologic disease. The presence or absence of these diseases was assessed through the question: “Has a doctor ever told you that you have [disease]?”; emergency room visit or hospital admission in the last 12 months (yes; no); polypharmacy (yes; no), considering as polypharmacy the current use of five or more drugs (excluding BZDs), including homeopathy, formulas made in a compounding pharmacy, florals, vitamins, and herbal medicines; and self-rated health (very good; good; fair; bad/very bad).</p>
			<p>Descriptive analysis of the independent variables was performed to characterize the sample; proportions and respective 95% confidence intervals were also calculated. The prevalence of BZD utilization in the 15 days prior to data collection was calculated, with its respective 95% confidence interval, general, and according to the independent variables. With the use of post-stratification weights, the direct relationship between the number of observations and the percentages is lost. Thus, the number of sample observations (n) was kept only in the titles of the tables. Poisson regression with robust variance was used to obtain the raw and adjusted prevalence ratios. In the adjusted analysis, a five-level hierarchical model was built based on the literature. The first level included the variables region of the country, sex, age, and skin color. The second level included the variables socioeconomic level (ABEP), schooling, and marital status. The third level integrated the variables health insurance, smoking, depression, and multimorbidity. In the fourth level, the variable emergency room visit or hospital admission in the last 12 months. The fifth level encompasses the variables polypharmacy, abusive consumption of alcohol in the last month, and self-rated health. The variables were adjusted for those of the same level and of the higher level(s). We used backward selection and kept the variables whose p were less than 0.20 in the final model. We considered a significance level of 5%. Data were analyzed using Stata version 15.1 (StataCorp, College Station, Texas, USA).</p>
			<p>The PNAUM was approved by the National Research Ethics Committee (Protocol 18947013.6.0000.0008) and by the Research Ethics Committee of the Universidade Federal do Rio Grande do Sul (Protocol 19997). All interviews were carried out after the interviewee or his legal guardian had read and signed an informed consent form.</p>
		</sec>
		<sec sec-type="results">
			<title>RESULTS</title>
			<p>A total of 9,019 individuals were included in this study. After adjustments in region, sex, and age, they represented approximately the 23 million older adults living in the urban area of Brazil.</p>
			<p>Women (57.7%), individuals aged between 60 and 69 years (52.3%), of white skin color (52.8%), belonging to the C socioeconomic level (54.7%), who lived with a partner (55.8%) and resided in the Southeast region (52.5%) predominated. Of the total, 9.5% and 41.5% had depression and multimorbidity respectively; 21.8% were polypharmacy users. About 4% reported abusive consumption of alcohol in the last month, with a wide difference between the sexes (women: 1%; 95%CI 0.7–1.5 versus men: 8.3%; 95%CI 7.0–9,8). Almost half of the sample had a self-rated health of good health ( <xref ref-type="table" rid="t1">Table 1</xref> ).</p>
			<p>
				<table-wrap id="t1">
					<label>Table 1</label>
					<caption>
						<title>Description of the sample, according to sociodemographic, behavioral, and health-related variables. PNAUM, 2014 (n = 9,019).</title>
					</caption>
					<table frame="hsides" rules="groups">
						<colgroup>
							<col/>
							<col/>
							<col/>
						</colgroup>
						<thead>
							<tr>
								<th align="left">Variables</th>
								<th>% <sup>a</sup></th>
								<th>95%CI</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td>Region</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>North</td>
								<td align="center">4.8</td>
								<td align="center">3.8–6.1</td>
							</tr>
							<tr>
								<td>Northeast</td>
								<td align="center">21.2</td>
								<td align="center">17.2–25.8</td>
							</tr>
							<tr>
								<td>Midwest</td>
								<td align="center">6.8</td>
								<td align="center">5.4–8.5</td>
							</tr>
							<tr>
								<td>Southeast</td>
								<td align="center">52.5</td>
								<td align="center">46.5–58.4</td>
							</tr>
							<tr>
								<td>South</td>
								<td align="center">14.7</td>
								<td align="center">11.8–18.1</td>
							</tr>
							<tr>
								<td>Sex</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Male</td>
								<td align="center">42.2</td>
								<td align="center">40.7–43.8</td>
							</tr>
							<tr>
								<td>Female</td>
								<td align="center">57.7</td>
								<td align="center">56.2–59.3</td>
							</tr>
							<tr>
								<td>Age</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>60–69 years</td>
								<td align="center">52.3</td>
								<td align="center">50.7–53.9</td>
							</tr>
							<tr>
								<td>70–79 years</td>
								<td align="center">32.4</td>
								<td align="center">31.0–33.9</td>
							</tr>
							<tr>
								<td>80 years or more</td>
								<td align="center">15.2</td>
								<td align="center">14.1–16.4</td>
							</tr>
							<tr>
								<td>Skin color</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>White</td>
								<td align="center">52.8</td>
								<td align="center">49.8–55.8</td>
							</tr>
							<tr>
								<td>Black</td>
								<td align="center">9.7</td>
								<td align="center">8.5–11.0</td>
							</tr>
							<tr>
								<td>Brown</td>
								<td align="center">36.0</td>
								<td align="center">33.4–38.7</td>
							</tr>
							<tr>
								<td>Yellow</td>
								<td align="center">1.2</td>
								<td align="center">0.9–1.6</td>
							</tr>
							<tr>
								<td>Indigenous</td>
								<td align="center">0.3</td>
								<td align="center">0.2–0.4</td>
							</tr>
							<tr>
								<td>Socioeconomic level (ABEP)</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>A–B</td>
								<td align="center">21.6</td>
								<td align="center">19.5–23.9</td>
							</tr>
							<tr>
								<td>C</td>
								<td align="center">54.7</td>
								<td align="center">52.7–56.6</td>
							</tr>
							<tr>
								<td>D</td>
								<td align="center">19.0</td>
								<td align="center">17.1–21.1</td>
							</tr>
							<tr>
								<td>E</td>
								<td align="center">4.6</td>
								<td align="center">4.0–5.5</td>
							</tr>
							<tr>
								<td>Schooling</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>0–4 years</td>
								<td align="center">38.9</td>
								<td align="center">36.8–40.9</td>
							</tr>
							<tr>
								<td>5–8 years</td>
								<td align="center">20.1</td>
								<td align="center">18.8–21.4</td>
							</tr>
							<tr>
								<td>9–11 years</td>
								<td align="center">30.1</td>
								<td align="center">28.5–31.7</td>
							</tr>
							<tr>
								<td>12 years or more</td>
								<td align="center">10.9</td>
								<td align="center">9.7–12.2</td>
							</tr>
							<tr>
								<td>Marital Status</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Without partner</td>
								<td align="center">44.2</td>
								<td align="center">42.3–46.1</td>
							</tr>
							<tr>
								<td>With partner</td>
								<td align="center">55.8</td>
								<td align="center">53.9–57.6</td>
							</tr>
							<tr>
								<td>Health insurance</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">73.0</td>
								<td align="center">70.1–75.6</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">27.0</td>
								<td align="center">24.3–29.9</td>
							</tr>
							<tr>
								<td>Smoking</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Never smoked</td>
								<td align="center">62.5</td>
								<td align="center">60.3–64.7</td>
							</tr>
							<tr>
								<td>Former smoker</td>
								<td align="center">26.9</td>
								<td align="center">25.1–28.8</td>
							</tr>
							<tr>
								<td>Current smoker</td>
								<td align="center">10.6</td>
								<td align="center">9.6–11.6</td>
							</tr>
							<tr>
								<td>Depression</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">90.5</td>
								<td align="center">89.4–91.4</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">9.5</td>
								<td align="center">8.6–10.6</td>
							</tr>
							<tr>
								<td>Multimorbidity</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">58.5</td>
								<td align="center">56.5–60.5</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">41.5</td>
								<td align="center">39.5–43.5</td>
							</tr>
							<tr>
								<td colspan="2">Emergency room visit or hospital admission in the last 12 months</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">78.7</td>
								<td align="center">77.2–80.2</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">21.3</td>
								<td align="center">19.8–22.8</td>
							</tr>
							<tr>
								<td>Polypharmacy</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">78.2</td>
								<td align="center">76.5–79.8</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">21.8</td>
								<td align="center">20.2–23.5</td>
							</tr>
							<tr>
								<td>Abusive alcohol consumption in the last month</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">95.9</td>
								<td align="center">95.2–96.5</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">4.1</td>
								<td align="center">3.5–4.8</td>
							</tr>
							<tr>
								<td>Self-rated health</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Very good</td>
								<td align="center">8.0</td>
								<td align="center">7.2–8.9</td>
							</tr>
							<tr>
								<td>Good</td>
								<td align="center">48.9</td>
								<td align="center">47.0–50.7</td>
							</tr>
							<tr>
								<td>Average</td>
								<td align="center">36.0</td>
								<td align="center">34.4–37.5</td>
							</tr>
							<tr>
								<td>Poor, very poor</td>
								<td align="center">7.1</td>
								<td align="center">6.4–7.9</td>
							</tr>
						</tbody>
					</table>
					<table-wrap-foot>
						<fn id="TFN1">
							<p><sup>a</sup> Percentages adjusted by sample weights and by post-stratification, according to age and sex.</p>
						</fn>
					</table-wrap-foot>
				</table-wrap>
			</p>
			<p>The prevalence of BZD utilization in older adults prior to 15 days of the survey data collection was 9.3% (95%CI 8.3–10.4). Considering the total number of BZD users, 59.3% (95%CI 54.0–64.4%) reported occasional utilization. Even so, 36.8% (95%CI 30.8–43.1) of them responded that the treatment would last “forever” and 27.2% (95%CI 21.9–33.2) that they would take the medication “whenever the symptoms returned”. Only 0.7% (95%CI 0.2–2.4) reported that they would no longer take the medication.</p>
			<p>Considering the total amount of BZD, those with the highest proportion of utilization were clonazepam (41.3%; 95%CI 36.7–46.0), diazepam (22.2%; 95%CI 18.2–26.9), bromazepam (14.5%; 95%CI 11.5–18.2), and alprazolam (9.6%; 95%CI 7.3–12.5) ( <xref ref-type="fig" rid="f01">Figure 1</xref> ). This pattern remained similar in all regions of the country. Regarding the BZD-related drugs, the prevalence of zolpidem utilization in older adults was 0.1% (95%CI 0.06–0.2).</p>
			<p>
				<fig id="f01">
					<label>Figure 1</label>
					<caption>
						<title>The proportion of benzodiazepines utilization by Brazilian older adults in the 15 days prior to data collection. PNAUM, 2014 (n = 699).</title>
					</caption>
					<graphic xlink:href="1518-8787-rsp-56-10-gf01.tif"/>
				</fig>
			</p>
			<p>
				<xref ref-type="fig" rid="f02">Figure 2</xref> shows the prevalence of BZD utilization in older adults by region, with sex stratification. We point that the prevalence of BZD utilization is consistently higher in women, although with important regional differences: while in the North Region the difference between the sexes is small, not reaching statistical significance, in the South and Central-West regions the variation is wide, reaching prevalences approximately two and three times higher in women than in men, respectively.</p>
			<p>
				<fig id="f02">
					<label>Figure 2</label>
					<caption>
						<title>Benzodiazepines utilization in Brazilian older adults in the 15 days prior to data collection, according to region and sex. PNAUM, 2014 (n = 9,019).</title>
					</caption>
					<graphic xlink:href="1518-8787-rsp-56-10-gf02.tif"/>
				</fig>
			</p>
			<p>The highest prevalence of BZD utilization was found in the following categories: female, South and Southeast regions, 70 years of age or older, white skin color, living without a partner, having health insurance, having depression or multimorbidity, visiting the emergency room or hospitalization in the last 12 months, polypharmacy, not reporting abusive consumption of alcohol in the last month and poor or very poor self-rated health ( <xref ref-type="table" rid="t2">Table 2</xref> ).</p>
			<p>
				<table-wrap id="t2">
					<label>Table 2</label>
					<caption>
						<title>Prevalence and crude prevalence ratios for the use of benzodiazepines in Brazilian older adults for the 15 days prior to survey data collection, according to sociodemographic, behavioral, and health-related variables. PNAUM, 2014 (n = 9,019).</title>
					</caption>
					<table frame="hsides" rules="groups">
						<colgroup>
							<col/>
							<col/>
							<col/>
							<col/>
							<col/>
						</colgroup>
						<thead>
							<tr>
								<th align="left">Variable</th>
								<th>Prevalence (%) <sup>a</sup></th>
								<th>CI95%</th>
								<th>Gross PR</th>
								<th>CI95%</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td>Region</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">p &lt; 0.001 <sup>b</sup></td>
							</tr>
							<tr>
								<td>North</td>
								<td align="center">1.8</td>
								<td align="center">1.3–2.6</td>
								<td align="center">0.18</td>
								<td align="center">0.12–0.26</td>
							</tr>
							<tr>
								<td>Northeast</td>
								<td align="center">8.2</td>
								<td align="center">7.1–9.7</td>
								<td align="center">0.81</td>
								<td align="center">0.66–0.99</td>
							</tr>
							<tr>
								<td>Midwest</td>
								<td align="center">6.1</td>
								<td align="center">4.8–7.6</td>
								<td align="center">0.60</td>
								<td align="center">0.46–0.77</td>
							</tr>
							<tr>
								<td>Southeast</td>
								<td align="center">10.2</td>
								<td align="center">8.5–12.2</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>South</td>
								<td align="center">11.5</td>
								<td align="center">9.6–13.7</td>
								<td align="center">1.13</td>
								<td align="center">0.92–1.38</td>
							</tr>
							<tr>
								<td>Sex</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">p &lt; 0.001 <sup>b</sup></td>
							</tr>
							<tr>
								<td>Male</td>
								<td align="center">6.0</td>
								<td align="center">5.0–7.1</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Female</td>
								<td align="center">11.8</td>
								<td align="center">10.3–13.4</td>
								<td align="center">1.97</td>
								<td align="center">1.60–2.43</td>
							</tr>
							<tr>
								<td>Age</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">p = 0.003 <sup>b</sup></td>
							</tr>
							<tr>
								<td>60–69 years</td>
								<td align="center">7.9</td>
								<td align="center">6.8–9.2</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>70–79 years</td>
								<td align="center">11.0</td>
								<td align="center">9.3–12.9</td>
								<td align="center">1.39</td>
								<td align="center">1.13–1.71</td>
							</tr>
							<tr>
								<td>80 years or more</td>
								<td align="center">10.6</td>
								<td align="center">8.3–13.3</td>
								<td align="center">1.34</td>
								<td align="center">1.04–1.73</td>
							</tr>
							<tr>
								<td>Skin color</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">p = 0.004 <sup>b</sup></td>
							</tr>
							<tr>
								<td>White</td>
								<td align="center">11.1</td>
								<td align="center">9.8–12.4</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Black</td>
								<td align="center">7.8</td>
								<td align="center">5.4–11.2</td>
								<td align="center">0.71</td>
								<td align="center">0.50–1.02</td>
							</tr>
							<tr>
								<td>Brown</td>
								<td align="center">8.0</td>
								<td align="center">6.7–9.5</td>
								<td align="center">0.72</td>
								<td align="center">0.59–0.89</td>
							</tr>
							<tr>
								<td>Socioeconomic level (ABEP)</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">p = 0.867 <sup>b</sup></td>
							</tr>
							<tr>
								<td>A–B</td>
								<td align="center">8.6</td>
								<td align="center">7.2–9.3</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>C</td>
								<td align="center">9.5</td>
								<td align="center">8.4–10.8</td>
								<td align="center">1.11</td>
								<td align="center">0.87–1.40</td>
							</tr>
							<tr>
								<td>D</td>
								<td align="center">9.4</td>
								<td align="center">7.4–12.0</td>
								<td align="center">1.09</td>
								<td align="center">0.82–1.44</td>
							</tr>
							<tr>
								<td>E</td>
								<td align="center">8.8</td>
								<td align="center">5.7–13.4</td>
								<td align="center">1.02</td>
								<td align="center">0.62–1.67</td>
							</tr>
							<tr>
								<td>Schooling</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">p = 0.185 <sup>b</sup></td>
							</tr>
							<tr>
								<td>0–4 years</td>
								<td align="center">10.4</td>
								<td align="center">8.8–9.1</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>5–8 years</td>
								<td align="center">8.2</td>
								<td align="center">6.7–10.2</td>
								<td align="center">0.79</td>
								<td align="center">0.62–1.01</td>
							</tr>
							<tr>
								<td>9–11 years</td>
								<td align="center">8.7</td>
								<td align="center">6.9–10.9</td>
								<td align="center">0.84</td>
								<td align="center">0.66–1.07</td>
							</tr>
							<tr>
								<td>12 years or more</td>
								<td align="center">8.4</td>
								<td align="center">6.3–10.9</td>
								<td align="center">0.80</td>
								<td align="center">0.59–1.10</td>
							</tr>
							<tr>
								<td>Marital Status</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">p &lt; 0.001 <sup>b</sup></td>
							</tr>
							<tr>
								<td>Without partner</td>
								<td align="center">11.5</td>
								<td align="center">9.8–13.4</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>With partner</td>
								<td align="center">7.9</td>
								<td align="center">6.9–9.1</td>
								<td align="center">0.69</td>
								<td align="center">0.57–0.83</td>
							</tr>
							<tr>
								<td>Health Insurance</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">p = 0.005 <sup>b</sup></td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">8.5</td>
								<td align="center">7.5–9.6</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">11.5</td>
								<td align="center">9.4–13.9</td>
								<td align="center">1.34</td>
								<td align="center">1.09–1.64</td>
							</tr>
							<tr>
								<td>Smoking</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">p = 0.450 <sup>a</sup></td>
							</tr>
							<tr>
								<td>Never smoked</td>
								<td align="center">9.3</td>
								<td align="center">8.0–10.8</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Former smoker</td>
								<td align="center">8.1</td>
								<td align="center">6.4–10.1</td>
								<td align="center">0.87</td>
								<td align="center">0.68–1.11</td>
							</tr>
							<tr>
								<td>Current smoker</td>
								<td align="center">9.8</td>
								<td align="center">7.6–12.7</td>
								<td align="center">1.05</td>
								<td align="center">0.79–1.41</td>
							</tr>
							<tr>
								<td>Depression</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">p &lt; 0.001 <sup>b</sup></td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">6.0</td>
								<td align="center">5.3–10.0</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">39.9</td>
								<td align="center">34.7–45.4</td>
								<td align="center">6.59</td>
								<td align="center">5.57–7.80</td>
							</tr>
							<tr>
								<td>Multimorbidity</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">p &lt; 0.001 <sup>b</sup></td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">6.2</td>
								<td align="center">5.3–7.3</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">13.6</td>
								<td align="center">11.9–15.6</td>
								<td align="center">2.88</td>
								<td align="center">2.37–3.50</td>
							</tr>
							<tr>
								<td>Emergency room visit or hospital admission in the last 12 months</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">p &lt; 0.001 <sup>b</sup></td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">7.7</td>
								<td align="center">6.8–8.8</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">15.1</td>
								<td align="center">12.8–17.8</td>
								<td align="center">1.95</td>
								<td align="center">1.60–2.38</td>
							</tr>
							<tr>
								<td>Polypharmacy</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">p &lt; 0.001 <sup>b</sup></td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">6.8</td>
								<td align="center">6.0–7.8</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">18.2</td>
								<td align="center">15.4–21.3</td>
								<td align="center">2.65</td>
								<td align="center">2.21–3.19</td>
							</tr>
							<tr>
								<td colspan="2">Abusive alcohol consumption in the last month</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">p &lt; 0.001 <sup>b</sup></td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">9.4</td>
								<td align="center">8.3–10.7</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">2.3</td>
								<td align="center">1.0–5.1</td>
								<td align="center">0.25</td>
								<td align="center">0.11–0.55</td>
							</tr>
							<tr>
								<td>Self-rated health</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">p &lt; 0.001 <sup>c</sup></td>
							</tr>
							<tr>
								<td>Very good</td>
								<td align="center">2.3</td>
								<td align="center">1.2–4.2</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Good</td>
								<td align="center">6.8</td>
								<td align="center">5.6–8.2</td>
								<td align="center">2.98</td>
								<td align="center">1.59–5.66</td>
							</tr>
							<tr>
								<td>Average</td>
								<td align="center">11.5</td>
								<td align="center">10.0–13.2</td>
								<td align="center">5.03</td>
								<td align="center">2.67–9.49</td>
							</tr>
							<tr>
								<td>Poor, very poor</td>
								<td align="center">23.0</td>
								<td align="center">17.9–29.0</td>
								<td align="center">10.0</td>
								<td align="center">5.16–19.50</td>
							</tr>
						</tbody>
					</table>
					<table-wrap-foot>
						<fn id="TFN2">
							<p><sup>a</sup> Percentages adjusted by sample weights and by post-stratification, according to age and sex. Only variables with p &lt; 0.20 were kept in the adjusted model.</p>
						</fn>
						<fn id="TFN3">
							<p><sup>b</sup> p value for the χ <sup>2</sup> test of heterogeneity</p>
						</fn>
						<fn id="TFN4">
							<p><sup>c</sup> p value for trend.</p>
						</fn>
						<fn id="TFN5">
							<p><sup>d</sup> Considering the reduced n, the “yellow” and “Indigenous” categories were transformed into <italic>missing</italic> for the regression model.</p>
						</fn>
					</table-wrap-foot>
				</table-wrap>
			</p>
			<p>After adjustments, the variables that did not remain in the hierarchical model were socioeconomic level, schooling, smoking, and health insurance (p &gt; 0.20). <xref ref-type="fig" rid="f03">Figure 3</xref> shows the adjusted prevalence ratios of the variables kept in the hierarchical model. Among them, only skin color and marital status were not significantly associated with BZD utilization in the adjusted analysis. The BZD utilization was five times higher in individuals with depression. It increased with the worsening of self-rated health. Individuals who reported abusive consumption of alcohol showed a 58% reduction in the risk of using BZD.</p>
			<p>
				<fig id="f03">
					<label>Figure 3</label>
					<caption>
						<title>Adjusted prevalence ratios for benzodiazepines utilization in Brazilian older adults in the 15 days prior to data collection. PNAUM, 2014 (n = 9,019).</title>
					</caption>
					<graphic xlink:href="1518-8787-rsp-56-10-gf03.tif"/>
					<attrib><sup>a</sup> Considering the reduced n, the “yellow” and “Indigenous” categories were transformed into missing for the regression model.</attrib>
				</fig>
			</p>
		</sec>
		<sec sec-type="discussion">
			<title>DISCUSSION</title>
			<p>This is the first population-based study representing the five Brazilian regions that evaluated the prevalence of BZD utilization in older adults. The prevalence found was 9.3%, higher than found in Saudi Arabia (4%) <sup><xref ref-type="bibr" rid="B13">13</xref></sup> and lower than that reported in France (31%) <sup><xref ref-type="bibr" rid="B14">14</xref></sup> , Finland (31%) <sup><xref ref-type="bibr" rid="B15">15</xref></sup> and Taiwan (43%) <sup><xref ref-type="bibr" rid="B16">16</xref></sup> . However, in absolute terms, it corresponds to more than two million older adults in Brazil, representing a large impact in terms of public health.</p>
			<p>The most frequently utilized medications were clonazepam and diazepam, medications among the BZDs that are provided free of charge by the Unified Health System (SUS) <sup><xref ref-type="bibr" rid="B17">17</xref></sup> . Most Brazilian studies found a similar pattern <sup><xref ref-type="bibr" rid="B18">18</xref></sup> . Only one study found higher consumption of alprazolam and bromazepam <sup><xref ref-type="bibr" rid="B2">2</xref></sup> , pattern also observed in most high-income countries where there is a tendency to opt for newer medications, with a short half-life. However, this study only used data from private pharmacies <sup><xref ref-type="bibr" rid="B2">2</xref></sup> .</p>
			<p>On the other hand, women, individuals aged between 70 and 79 years, with depression or multimorbidity, who reported at least one emergency visit or hospitalization in the last 12 months, polypharmacy and poor or very poor self-rated health, had a lower utilization prevalence than residents in the North Region and individuals who reported abusive consumption of alcohol in the last month.</p>
			<p>The present study has some disadvantages, related to the growing increase in losses and refusals observed in population surveys <sup><xref ref-type="bibr" rid="B10">10</xref></sup> . Published sample characterization data show household response rates of 51.7% and 51.5% for men and women, respectively. This is an underestimated proportion because it included vacant households in the calculation. A weak but statistically significant negative correlation was also found between the average income of the census tract and the response rate in all regions of the country <sup><xref ref-type="bibr" rid="B10">10</xref></sup> . However, other studies that evaluated older adults did not find a statistically significant association between socioeconomic status and BZD utilization <sup><xref ref-type="bibr" rid="B3">3</xref></sup> , reducing the possibility of selection bias. Residents’ response rates were similar between men and women (90.1% and 93.7%, respectively) <sup><xref ref-type="bibr" rid="B10">10</xref></sup> .</p>
			<p>Regarding the interviewee’s sex, women were about twice as likely as men to utilize BZD, a consistent finding in the literature <sup><xref ref-type="bibr" rid="B19">19</xref></sup> . Some questions are guided to explain this difference. Firstly, studies show that women have more depressive and anxiety disorders, while men have more addictive and externalizing disorders <sup><xref ref-type="bibr" rid="B3">3</xref></sup> . Since BZDs are used especially in the treatment of the former, their utilization may be a <italic>proxy</italic> for sex differences in the prevalence of mental disorders <sup><xref ref-type="bibr" rid="B20">20</xref></sup> , strongly impacted by the degree of sex inequality within a patriarchal society. Another relevant issue is that women seek more health services to treat mental health problems <sup><xref ref-type="bibr" rid="B3">3</xref> , <xref ref-type="bibr" rid="B20">20</xref></sup> . In the context of older adults, this finding has particular clinical relevance, considering the increased risk of falls after BZD utilization and the high risk of fractures in older women, especially hip fractures, which occur with high morbidity and mortality <sup><xref ref-type="bibr" rid="B21">21</xref></sup> .</p>
			<p>Broad regional differences were detected, with the prevalence of BZD utilization in the North Region (1.8%) being much lower than that found in other regions. Studies carried out in Brazil that evaluated the BZD utilization in the general population found a similar pattern <sup><xref ref-type="bibr" rid="B2">2</xref> , <xref ref-type="bibr" rid="B3">3</xref></sup> . They pointed out the increased consumption in cities with greater population density and a higher percentage of physicians <sup><xref ref-type="bibr" rid="B2">2</xref></sup> . Factors such as chaotic traffic, a feeling of insecurity, a competitive environment, great consumerist appeal, and low social cohesion make up the lifestyle of today’s large cities. These factors compromise the well-being of inhabitants and may contribute to the greater BZD utilization observed in these places <sup><xref ref-type="bibr" rid="B2">2</xref></sup> . It is also important to consider that the sale of BZDs has been controlled in Brazil since 1998 <sup><xref ref-type="bibr" rid="B1">1</xref></sup> , so access to medical prescriptions is a determining factor in their utilization. Medication access is likely to be difficult in regions that have a lower number of physicians per inhabitant: while the country has an average ratio of 2.27 physicians per thousand inhabitants, the North Region has a rate of 1.30, 43% lower than the national average ratio <sup><xref ref-type="bibr" rid="B22">22</xref></sup> .</p>
			<p>Previous diagnosis of depression was the most important independent variable to predict the BZD utilization in older adults. Individuals with a history of depression had a prevalence of use of 39.9% and, even after an adjusted analysis, were five times more likely to use BZD than individuals without a diagnosis of depression. Similar findings were found in other studies that evaluated the BZD utilization in the general population and in the older adults <sup><xref ref-type="bibr" rid="B23">23</xref></sup> .</p>
			<p>Antidepressant drugs (AD) are the treatment of choice for depression and are also effective for the treatment of coexisting anxiety symptoms. However, the beneficial effects of AD are usually only obtained after several weeks, during which time BZDs are usually prescribed for a immediate relief of symptoms <sup><xref ref-type="bibr" rid="B24">24</xref></sup> . However, the benefit of the combined treatment is not sustained for more than four weeks <sup><xref ref-type="bibr" rid="B25">25</xref></sup> . Nevertheless, the prevalence of long-term BZD utilization in older adults is high <sup><xref ref-type="bibr" rid="B24">24</xref></sup> . Qualitative studies pointed out the renewal of prescriptions initiated by other physicians as a possible cause, seeking to meet patients’ requests and avoid damage to the doctor-patient relationship <sup><xref ref-type="bibr" rid="B26">26</xref></sup> . It is important to emphasize that dependence on BZDs occurs within a few weeks of regular use and is associated with withdrawal syndrome, characterized by the occurrence of sleep disorders, anxiety, and agoraphobia after medication discontinuation, especially when performed abruptly. The intensity of symptoms can explain relapses after attempts to stop, resulting in the perpetuation of use <sup><xref ref-type="bibr" rid="B27">27</xref></sup> .</p>
			<p>Multimorbidity and polypharmacy showed an increase of 1.4 and 1.3 times, respectively, in the probability of using BZD. This finding reflects a greater burden of disease and greater risk of anxiety disorders <sup><xref ref-type="bibr" rid="B19">19</xref></sup> . Both conditions are more prevalent in older adults and are associated with a higher risk of iatrogenesis, functional deterioration, loss of independence, and autonomy <sup><xref ref-type="bibr" rid="B8">8</xref></sup> . Users of a greater number of medications are still at high risk of medical interactions and adverse events such as confusion, agitation, and delirium. These symptoms can be confused with anxiety and lead to the prescription of BZD, worsening the conditions <sup><xref ref-type="bibr" rid="B19">19</xref></sup> .</p>
			<p>Individuals who reported abusive consumption of alcohol in the last month showed a reduction in the probability of using BZD (PR = 0.42; 95%CI 0.19–0.94). Most studies that evaluated alcohol consumption in the last month found similar findings <sup><xref ref-type="bibr" rid="B14">14</xref> , <xref ref-type="bibr" rid="B18">18</xref> , <xref ref-type="bibr" rid="B19">19</xref></sup> . It is known that alcohol and BZDs share common mechanisms of action <sup><xref ref-type="bibr" rid="B3">3</xref></sup> and potentially produce comparable effects on baseline anxiety and sleep, leading individuals to feel the need for one or the other, but not for both <sup><xref ref-type="bibr" rid="B19">19</xref></sup> . In part, this choice seems to be influenced by the individual’s sex. The present study found a higher prevalence of BZD utilization in women and alcohol consumption by men. It is also possible that this difference results from a lower number of BZD prescriptions among alcohol users, since the effect of the two substances as respiratory center depressants is synergistic, resulting in serious and potentially fatal intoxications <sup><xref ref-type="bibr" rid="B18">18</xref></sup> .</p>
			<p>Only one study found the opposite association, in which alcohol abuse determined greater BZD utilization (OR 3.1–95%CI 1.7–5.7) <sup><xref ref-type="bibr" rid="B3">3</xref></sup> . However, this study included the general population and used a 12-month recall period for both alcohol abuse and BZD utilization. In a mediation analysis, the authors noted that the effect of alcohol on BZD utilization was both direct and indirect, including depressive symptoms, physical inactivity, and sleep disturbances. Because they have common mechanisms of action, we point out that alcohol and BZD could lead to cross-tolerance. Thus, BZD-dependent individuals may choose to use alcohol during periods of deprivation, in the same way that the BZD class is part of the treatment for alcohol withdrawal syndrome <sup><xref ref-type="bibr" rid="B3">3</xref></sup> . This phenomenon could also justify our findings, given alcohol abuse is the most proximal determinant in the hierarchical model. Thus, an integrated approach to the treatment of both conditions is needed.</p>
			<p>Emergency room visits or hospital admissions in the last 12 months were also associated with a higher BZD prescription for older adults, with a 1.4-fold increased risk. Recent studies have shown a high prevalence of older adults receiving BZD during hospitalization. This is a serious issue because new BZD prescriptions given to older patients at hospital discharge can lead to chronic medication utilization <sup><xref ref-type="bibr" rid="B28">28</xref></sup> .</p>
			<p>Therefore, it is important to emphasize that the prevalence of over-the-counter BZD utilization found in the literature varies from 3.3% to 8.4% <sup><xref ref-type="bibr" rid="B2">2</xref></sup> , demonstrating that efforts aimed at increasing supervision over the sale of the drug are not enough to solve the problem, since most users obtain that medication by medical prescription. Thus, the rational BZD utilization starts from the appreciation of continuing medical education and the encouragement of multi-professional partnerships <sup><xref ref-type="bibr" rid="B2">2</xref> , <xref ref-type="bibr" rid="B9">9</xref></sup> , based on comprehensive care for older patients, with the objective of reducing avoidable adverse events, and maximizing the independence and autonomy of these individuals <sup><xref ref-type="bibr" rid="B8">8</xref></sup> .</p>
			<p>The relevance of the topic requires further investigation, especially in the covid-19 post-pandemic context <sup><xref ref-type="bibr" rid="B29">29</xref></sup> . Emerging evidence have shown dramatic impacts on individuals’ mental health, with increased anxiety and social isolation due to physical distancing policies introduced for infection control <sup><xref ref-type="bibr" rid="B30">30</xref></sup> , particularly affecting the older adults. It is likely that the high prevalence of BZD utilization will increase even more in this context. Once the public health emergency related to the pandemic itself is controlled, public policies promoting the rational utilization of this drug class are needed.</p>
			<p>Despite the potential limitations inherent to a cross-sectional study, especially in relation to causal inference, the present study brought consistent and nationally representative data, hitherto unexplored by literature. Despite recommendations against its use <sup><xref ref-type="bibr" rid="B6">6</xref></sup> , the results revealed a high prevalence of BZD utilization in older individuals, particularly in those with depression, in addition to wide differences in relation to the region of the country and the individual’s sex.</p>
		</sec>
	</body>
	<back>
		<ack>
			<title>Acknowledgments</title>
			<p>To the Ministry of Health, for the funding and technical support to carry out the <italic>Pesquisa Nacional sobre Acesso, Utilização e Promoção do Uso Racional de Medicamentos</italic> (National Survey on Access, Use, and Promotion of Rational Use of Medicines); to Thiago Melo, for the collaboration in the graphic material.</p>
		</ack>
		<ref-list>
			<title>REFERENCES</title>
			<ref id="B1">
				<label>1</label>
				<mixed-citation>1. Fiorelli K , Assini FL . A prescrição de benzodiazepínicos no Brasil: uma análise da literatura . ABCS Health Sci . 2017 ; 42 ( 1 ): 40 - 4 .</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Fiorelli</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Assini</surname>
							<given-names>FL</given-names>
						</name>
					</person-group>
					<article-title>A prescrição de benzodiazepínicos no Brasil: uma análise da literatura</article-title>
					<source>ABCS Health Sci</source>
					<year>2017</year>
					<volume>42</volume>
					<issue>1</issue>
					<fpage>40</fpage>
					<lpage>44</lpage>
				</element-citation>
			</ref>
			<ref id="B2">
				<label>2</label>
				<mixed-citation>2. Azevedo AJP , Araújo AA , Ferreira MAF . Consumo de ansiolíticos benzodiazepínicos: uma correlação entre dados do SNGPC e indicadores sociodemográficos nas capitais brasileiras . Cienc Saude Coletiva . 2016 ; 21 ( 1 ): 83 - 90 . <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/1413-81232015211.15532014">https://doi.org/10.1590/1413-81232015211.15532014</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Azevedo</surname>
							<given-names>AJP</given-names>
						</name>
						<name>
							<surname>Araújo</surname>
							<given-names>AA</given-names>
						</name>
						<name>
							<surname>Ferreira</surname>
							<given-names>MAF</given-names>
						</name>
					</person-group>
					<article-title>Consumo de ansiolíticos benzodiazepínicos: uma correlação entre dados do SNGPC e indicadores sociodemográficos nas capitais brasileiras</article-title>
					<source>Cienc Saude Coletiva</source>
					<year>2016</year>
					<volume>21</volume>
					<issue>1</issue>
					<fpage>83</fpage>
					<lpage>90</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/1413-81232015211.15532014">https://doi.org/10.1590/1413-81232015211.15532014</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B3">
				<label>3</label>
				<mixed-citation>3. Madruga CS , Paim TL , Palhares HN , Miguel AC , Massaro LTS , Caetano R , et al . Prevalence of and pathways to benzodiazepine use in Brazil: the role of depression, sleep, and sedentary lifestyle . Braz J. Psichiatry . 2019 ; 41 ( 1 ): 44 - 50 . <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/1516-4446-2018-0088">https://doi.org/10.1590/1516-4446-2018-0088</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Madruga</surname>
							<given-names>CS</given-names>
						</name>
						<name>
							<surname>Paim</surname>
							<given-names>TL</given-names>
						</name>
						<name>
							<surname>Palhares</surname>
							<given-names>HN</given-names>
						</name>
						<name>
							<surname>Miguel</surname>
							<given-names>AC</given-names>
						</name>
						<name>
							<surname>Massaro</surname>
							<given-names>LTS</given-names>
						</name>
						<name>
							<surname>Caetano</surname>
							<given-names>R</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Prevalence of and pathways to benzodiazepine use in Brazil: the role of depression, sleep, and sedentary lifestyle</article-title>
					<source>Braz J. Psichiatry</source>
					<year>2019</year>
					<volume>41</volume>
					<issue>1</issue>
					<fpage>44</fpage>
					<lpage>50</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/1516-4446-2018-0088">https://doi.org/10.1590/1516-4446-2018-0088</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B4">
				<label>4</label>
				<mixed-citation>4. Kurko TA , Saastamoinen LK , Tähkäpää S , Tuulio-Henriksson A , Taiminen T , Tiihonen J , et al . Long-term use of benzodiazepines: definitions, prevalence and usage patterns a systematic review of register-based studies . Eur Psychiatry . 2015 ; 30 ( 8 ): 1037 - 47 . <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.eurpsy.2015.09.003">https://doi.org/10.1016/j.eurpsy.2015.09.003</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kurko</surname>
							<given-names>TA</given-names>
						</name>
						<name>
							<surname>Saastamoinen</surname>
							<given-names>LK</given-names>
						</name>
						<name>
							<surname>Tähkäpää</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Tuulio-Henriksson</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Taiminen</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Tiihonen</surname>
							<given-names>J</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Long-term use of benzodiazepines: definitions, prevalence and usage patterns a systematic review of register-based studies</article-title>
					<source>Eur Psychiatry</source>
					<year>2015</year>
					<volume>30</volume>
					<issue>8</issue>
					<fpage>1037</fpage>
					<lpage>1047</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.eurpsy.2015.09.003">https://doi.org/10.1016/j.eurpsy.2015.09.003</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B5">
				<label>5</label>
				<mixed-citation>5. Carrière I , Mura T , Pérès K , Norton J , Jaussent I , Edjolo A , et al . Elderly benzodiazepine users at increased risk of activity limitations: influence of chronicity, indications, and duration of action: the three-city cohort . Am J Geriatr Psychiatry . 2015 ; 23 ( 8 ): 840 - 51 . <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jagp.2014.10.006">https://doi.org/10.1016/j.jagp.2014.10.006</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Carrière</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Mura</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Pérès</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Norton</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Jaussent</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Edjolo</surname>
							<given-names>A</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Elderly benzodiazepine users at increased risk of activity limitations: influence of chronicity, indications, and duration of action: the three-city cohort</article-title>
					<source>Am J Geriatr Psychiatry</source>
					<year>2015</year>
					<volume>23</volume>
					<issue>8</issue>
					<fpage>840</fpage>
					<lpage>851</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jagp.2014.10.006">https://doi.org/10.1016/j.jagp.2014.10.006</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B6">
				<label>6</label>
				<mixed-citation>6. American Geriatrics Society Beers Criteria Update Expert Panel . American Geriatrics Society 2019 updated AGS Beers Criteria for potentially inappropriate medication use in older adults . J Am Geriatr Soc . 2019 ; 67 ( 4 ): 674 - 94</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<collab>American Geriatrics Society Beers Criteria Update Expert Panel</collab>
					</person-group>
					<article-title>American Geriatrics Society 2019 updated AGS Beers Criteria for potentially inappropriate medication use in older adults</article-title>
					<source>J Am Geriatr Soc</source>
					<year>2019</year>
					<volume>67</volume>
					<issue>4</issue>
					<fpage>674</fpage>
					<lpage>694</lpage>
				</element-citation>
			</ref>
			<ref id="B7">
				<label>7</label>
				<mixed-citation>7. Cunningham CM , Hanley GE , Morgan S . Patterns in the use of benzodiazepines in British Columbia: examining the impact of increasing research and guideline cautions against long-term use . Health Policy . 2010 ; 97 ( 2-3 ): 122 - 9 . <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.healthpol.2010.03.008">https://doi.org/10.1016/j.healthpol.2010.03.008</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Cunningham</surname>
							<given-names>CM</given-names>
						</name>
						<name>
							<surname>Hanley</surname>
							<given-names>GE</given-names>
						</name>
						<name>
							<surname>Morgan</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Patterns in the use of benzodiazepines in British Columbia: examining the impact of increasing research and guideline cautions against long-term use</article-title>
					<source>Health Policy</source>
					<year>2010</year>
					<volume>97</volume>
					<season>2-3</season>
					<fpage>122</fpage>
					<lpage>129</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.healthpol.2010.03.008">https://doi.org/10.1016/j.healthpol.2010.03.008</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B8">
				<label>8</label>
				<mixed-citation>8. Ramos LR , Tavares NUL , Bertoldi AD , Farias MR , Oliveira MA , Luiza VL , et al . Polifarmácia e polimorbidade em idosos no Brasil: um desafio em saúde pública . Rev Saude Publica 2016 ; 50 Supl 2 : 9s . <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/S1518-8787.2016050006145">https://doi.org/10.1590/S1518-8787.2016050006145</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ramos</surname>
							<given-names>LR</given-names>
						</name>
						<name>
							<surname>Tavares</surname>
							<given-names>NUL</given-names>
						</name>
						<name>
							<surname>Bertoldi</surname>
							<given-names>AD</given-names>
						</name>
						<name>
							<surname>Farias</surname>
							<given-names>MR</given-names>
						</name>
						<name>
							<surname>Oliveira</surname>
							<given-names>MA</given-names>
						</name>
						<name>
							<surname>Luiza</surname>
							<given-names>VL</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Polifarmácia e polimorbidade em idosos no Brasil: um desafio em saúde pública</article-title>
					<source>Rev Saude Publica</source>
					<year>2016</year>
					<volume>50</volume>
					<supplement>Supl 2</supplement>
					<size units="pages">9s</size>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/S1518-8787.2016050006145">https://doi.org/10.1590/S1518-8787.2016050006145</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B9">
				<label>9</label>
				<mixed-citation>9. Ministério da Saúde (BR) , Secretaria de Ciência, Tecnologia e Insumos Estratégicos , Departamento de Assistência Farmacêutica e Insumos Estratégicos ; Comitê Nacional para Promoção do Uso Racional de Medicamentos . Uso de medicamentos e medicalização da vida: recomendações e estratégias . Brasília, DF ; 2019 [ cited 2019 Nov 23 ]. Available from: <ext-link ext-link-type="uri" xlink:href="https://portalarquivos2.saude.gov.br/images/pdf/2019/fevereiro/14/ERRATA-Livro-USO-DE-MEDICAMENTOS-E-MEDICALIZACAO-DA-VIDA.pdf">https://portalarquivos2.saude.gov.br/images/pdf/2019/fevereiro/14/ERRATA-Livro-USO-DE-MEDICAMENTOS-E-MEDICALIZACAO-DA-VIDA.pdf</ext-link>
				</mixed-citation>
				<element-citation publication-type="webpage">
					<person-group person-group-type="author">
						<collab>Ministério da Saúde (BR)</collab>
						<collab>Secretaria de Ciência, Tecnologia e Insumos Estratégicos</collab>
						<collab>Departamento de Assistência Farmacêutica e Insumos Estratégicos</collab>
						<collab>Comitê Nacional para Promoção do Uso Racional de Medicamentos</collab>
					</person-group>
					<source>Uso de medicamentos e medicalização da vida: recomendações e estratégias</source>
					<publisher-loc>Brasília, DF</publisher-loc>
					<year>2019</year>
					<date-in-citation content-type="cited-date">cited 2019 Nov 23</date-in-citation>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://portalarquivos2.saude.gov.br/images/pdf/2019/fevereiro/14/ERRATA-Livro-USO-DE-MEDICAMENTOS-E-MEDICALIZACAO-DA-VIDA.pdf">https://portalarquivos2.saude.gov.br/images/pdf/2019/fevereiro/14/ERRATA-Livro-USO-DE-MEDICAMENTOS-E-MEDICALIZACAO-DA-VIDA.pdf</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B10">
				<label>10</label>
				<mixed-citation>10. Mengue SS , Bertoldi AD , Boing AC , Tavares NUL , Dal Pizzol TS , Oliveira MA , et al . Pesquisa Nacional sobre Acesso, Utilização e Promoção do Uso Racional de Medicamentos (PNAUM): métodos do inquérito domiciliar . Rev Saude Publica . 2016 ; 50 Supl 2 : 4s . <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/S1518-8787.2016050006156">https://doi.org/10.1590/S1518-8787.2016050006156</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mengue</surname>
							<given-names>SS</given-names>
						</name>
						<name>
							<surname>Bertoldi</surname>
							<given-names>AD</given-names>
						</name>
						<name>
							<surname>Boing</surname>
							<given-names>AC</given-names>
						</name>
						<name>
							<surname>Tavares</surname>
							<given-names>NUL</given-names>
						</name>
						<name>
							<surname>Dal Pizzol</surname>
							<given-names>TS</given-names>
						</name>
						<name>
							<surname>Oliveira</surname>
							<given-names>MA</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Pesquisa Nacional sobre Acesso, Utilização e Promoção do Uso Racional de Medicamentos (PNAUM): métodos do inquérito domiciliar</article-title>
					<source>Rev Saude Publica</source>
					<year>2016</year>
					<volume>50</volume>
					<supplement>Supl 2</supplement>
					<size units="pages">4s</size>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/S1518-8787.2016050006156">https://doi.org/10.1590/S1518-8787.2016050006156</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B11">
				<label>11</label>
				<mixed-citation>11. WHO Collaborating Centre for Drug Statistics Methodology . ATC/DDD Index 2018 . Oslo (NO) ; 2019 .</mixed-citation>
				<element-citation publication-type="report">
					<person-group person-group-type="author">
						<collab>WHO Collaborating Centre for Drug Statistics Methodology</collab>
					</person-group>
					<source>ATC/DDD Index 2018</source>
					<publisher-loc>Oslo (NO)</publisher-loc>
					<year>2019</year>
				</element-citation>
			</ref>
			<ref id="B12">
				<label>12</label>
				<mixed-citation>12. Associação Brasileira de Empresas de Pesquisa . Critério de Classificação Econômica Brasil 2013 . São Paulo : ABEP ; 2013 .</mixed-citation>
				<element-citation publication-type="report">
					<person-group person-group-type="author">
						<collab>Associação Brasileira de Empresas de Pesquisa</collab>
					</person-group>
					<source>Critério de Classificação Econômica Brasil 2013</source>
					<publisher-loc>São Paulo</publisher-loc>
					<publisher-name>ABEP</publisher-name>
					<year>2013</year>
				</element-citation>
			</ref>
			<ref id="B13">
				<label>13</label>
				<mixed-citation>13. Aljawadi MH , Khoja AT , Alhammad AM , AlOtaibi AD , Al-Shammari SA , Khoja TA . The prevalence of benzodiazepines utilization and its association with falls among Saudi older adults; results from the Saudi National Survey for Elderly Health (SNSEH) . Saudi Pharm J . 2018 ; 26 ( 8 ): 1112 - 9 . <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jsps.2018.05.022">https://doi.org/10.1016/j.jsps.2018.05.022</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Aljawadi</surname>
							<given-names>MH</given-names>
						</name>
						<name>
							<surname>Khoja</surname>
							<given-names>AT</given-names>
						</name>
						<name>
							<surname>Alhammad</surname>
							<given-names>AM</given-names>
						</name>
						<name>
							<surname>AlOtaibi</surname>
							<given-names>AD</given-names>
						</name>
						<name>
							<surname>Al-Shammari</surname>
							<given-names>SA</given-names>
						</name>
						<name>
							<surname>Khoja</surname>
							<given-names>TA</given-names>
						</name>
					</person-group>
					<article-title>The prevalence of benzodiazepines utilization and its association with falls among Saudi older adults; results from the Saudi National Survey for Elderly Health (SNSEH)</article-title>
					<source>Saudi Pharm J</source>
					<year>2018</year>
					<volume>26</volume>
					<issue>8</issue>
					<fpage>1112</fpage>
					<lpage>1119</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jsps.2018.05.022">https://doi.org/10.1016/j.jsps.2018.05.022</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B14">
				<label>14</label>
				<mixed-citation>14. Fourrier A , Letenneur L , Dartigues JF , Moore N , Bégaud B . Benzodiazepine use in an elderly community-dwelling population. Characteristics of users and factors associated with subsequent use . Eur J Clin Pharmacol . 2001 ; 57 ( 5 ): 419 - 25 . <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s002280100326">https://doi.org/10.1007/s002280100326</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Fourrier</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Letenneur</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Dartigues</surname>
							<given-names>JF</given-names>
						</name>
						<name>
							<surname>Moore</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Bégaud</surname>
							<given-names>B</given-names>
						</name>
					</person-group>
					<article-title>Benzodiazepine use in an elderly community-dwelling population. Characteristics of users and factors associated with subsequent use</article-title>
					<source>Eur J Clin Pharmacol</source>
					<year>2001</year>
					<volume>57</volume>
					<issue>5</issue>
					<fpage>419</fpage>
					<lpage>425</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s002280100326">https://doi.org/10.1007/s002280100326</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B15">
				<label>15</label>
				<mixed-citation>15. Rikala M , Korhonen MJ , Sulkava R , Hartikainen S . Psychotropic drug use in community-dwelling elderly people-characteristics of persistent and incident users . Eur J Clin Pharmacol . 2011 ; 67 ( 7 ): 731 - 9 . <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00228-011-0996-5">https://doi.org/10.1007/s00228-011-0996-5</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Rikala</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Korhonen</surname>
							<given-names>MJ</given-names>
						</name>
						<name>
							<surname>Sulkava</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Hartikainen</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Psychotropic drug use in community-dwelling elderly people-characteristics of persistent and incident users</article-title>
					<source>Eur J Clin Pharmacol</source>
					<year>2011</year>
					<volume>67</volume>
					<issue>7</issue>
					<fpage>731</fpage>
					<lpage>739</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00228-011-0996-5">https://doi.org/10.1007/s00228-011-0996-5</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B16">
				<label>16</label>
				<mixed-citation>16. Cheng JS , Huang WF , Lin KM , Shih YT . Characteristics associated with benzodiazepine usage in elderly outpatients in Taiwan . Int J Geriatr Psychiatry . 2008 ; 23 ( 6 ): 618 - 24 . <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/gps.1950">https://doi.org/10.1002/gps.1950</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Cheng</surname>
							<given-names>JS</given-names>
						</name>
						<name>
							<surname>Huang</surname>
							<given-names>WF</given-names>
						</name>
						<name>
							<surname>Lin</surname>
							<given-names>KM</given-names>
						</name>
						<name>
							<surname>Shih</surname>
							<given-names>YT</given-names>
						</name>
					</person-group>
					<article-title>Characteristics associated with benzodiazepine usage in elderly outpatients in Taiwan</article-title>
					<source>Int J Geriatr Psychiatry</source>
					<year>2008</year>
					<volume>23</volume>
					<issue>6</issue>
					<fpage>618</fpage>
					<lpage>624</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/gps.1950">https://doi.org/10.1002/gps.1950</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B17">
				<label>17</label>
				<mixed-citation>17. Ministério da Saúde (BR) , Secretaria de Ciência, Tecnologia e Insumos Estratégicos , Departamento de Assistência Farmacêutica e Insumos Estratégicos . Relação Nacional de Medicamentos Essenciais: RENAME 2018 . Brasília, DF ; 2018 [ cited 2019 Nov 23 ]. Available from: <ext-link ext-link-type="uri" xlink:href="http://bvsms.saude.gov.br/bvs/publicacoes/medicamentos_rename.pdf">http://bvsms.saude.gov.br/bvs/publicacoes/medicamentos_rename.pdf</ext-link>
				</mixed-citation>
				<element-citation publication-type="webpage">
					<person-group person-group-type="author">
						<collab>Ministério da Saúde (BR)</collab>
						<collab>Secretaria de Ciência, Tecnologia e Insumos Estratégicos</collab>
						<collab>Departamento de Assistência Farmacêutica e Insumos Estratégicos</collab>
					</person-group>
					<source>Relação Nacional de Medicamentos Essenciais: RENAME 2018</source>
					<publisher-loc>Brasília, DF</publisher-loc>
					<year>2018</year>
					<date-in-citation content-type="cited-date">cited 2019 Nov 23</date-in-citation>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="http://bvsms.saude.gov.br/bvs/publicacoes/medicamentos_rename.pdf">http://bvsms.saude.gov.br/bvs/publicacoes/medicamentos_rename.pdf</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B18">
				<label>18</label>
				<mixed-citation>18. Cunha CDA , Souza MCC , Cattanio GAA , Iahnn SR , Lima RC . Benzodiazepine use and associated factors in elderly in the city of Dourados, MS, Brazil . J Bras Psiquiatr . 2015 ; 64 ( 3 ): 207 - 12 . <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/0047-2085000000080">https://doi.org/10.1590/0047-2085000000080</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Cunha</surname>
							<given-names>CDA</given-names>
						</name>
						<name>
							<surname>Souza</surname>
							<given-names>MCC</given-names>
						</name>
						<name>
							<surname>Cattanio</surname>
							<given-names>GAA</given-names>
						</name>
						<name>
							<surname>Iahnn</surname>
							<given-names>SR</given-names>
						</name>
						<name>
							<surname>Lima</surname>
							<given-names>RC</given-names>
						</name>
					</person-group>
					<article-title>Benzodiazepine use and associated factors in elderly in the city of Dourados, MS, Brazil</article-title>
					<source>J Bras Psiquiatr</source>
					<year>2015</year>
					<volume>64</volume>
					<issue>3</issue>
					<fpage>207</fpage>
					<lpage>212</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/0047-2085000000080">https://doi.org/10.1590/0047-2085000000080</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B19">
				<label>19</label>
				<mixed-citation>19. Stowell KR , Chang CC , Bilt J , Stoehr GP , Ganguli M . Sustained benzodiazepine use in a community sample of older adults . J Am Geriatr Soc . 2008 ; 56 ( 12 ): 2285 - 91 . <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1532-5415.2008.02011.x">https://doi.org/10.1111/j.1532-5415.2008.02011.x</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Stowell</surname>
							<given-names>KR</given-names>
						</name>
						<name>
							<surname>Chang</surname>
							<given-names>CC</given-names>
						</name>
						<name>
							<surname>Bilt</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Stoehr</surname>
							<given-names>GP</given-names>
						</name>
						<name>
							<surname>Ganguli</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Sustained benzodiazepine use in a community sample of older adults</article-title>
					<source>J Am Geriatr Soc</source>
					<year>2008</year>
					<volume>56</volume>
					<issue>12</issue>
					<fpage>2285</fpage>
					<lpage>2291</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1532-5415.2008.02011.x">https://doi.org/10.1111/j.1532-5415.2008.02011.x</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B20">
				<label>20</label>
				<mixed-citation>20. Boyd A , Van de Velde S , Pivette M , Ten Have M , Florescu S , O’Neill S , et al . Gender differences in psychotropic use across Europe: results from a large cross-sectional, population-based study . Eur Psychiatry . 2015 ; 30 ( 6 ): 778 - 88 . <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.eurpsy.2015.05.001">https://doi.org/10.1016/j.eurpsy.2015.05.001</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Boyd</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Van de Velde</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Pivette</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Ten Have</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Florescu</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>O’Neill</surname>
							<given-names>S</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Gender differences in psychotropic use across Europe: results from a large cross-sectional, population-based study</article-title>
					<source>Eur Psychiatry</source>
					<year>2015</year>
					<volume>30</volume>
					<issue>6</issue>
					<fpage>778</fpage>
					<lpage>788</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.eurpsy.2015.05.001">https://doi.org/10.1016/j.eurpsy.2015.05.001</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B21">
				<label>21</label>
				<mixed-citation>21. Cumming RG , Le Couteur DG . Benzodiazepines and risk of hip fractures in older people: a review of the evidence . CNS Drugs . 2003 ; 17 ( 11 ): 825 - 37 . <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2165/00023210-200317110-00004">https://doi.org/10.2165/00023210-200317110-00004</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Cumming</surname>
							<given-names>RG</given-names>
						</name>
						<name>
							<surname>Le Couteur</surname>
							<given-names>DG</given-names>
						</name>
					</person-group>
					<article-title>Benzodiazepines and risk of hip fractures in older people: a review of the evidence</article-title>
					<source>CNS Drugs</source>
					<year>2003</year>
					<volume>17</volume>
					<issue>11</issue>
					<fpage>825</fpage>
					<lpage>837</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2165/00023210-200317110-00004">https://doi.org/10.2165/00023210-200317110-00004</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B22">
				<label>22</label>
				<mixed-citation>22. Scheffer M , coordenador . Demografia Médica no Brasil 2020 . São Paulo : Departamento de Medicina Preventiva da Faculdade de Medicina da USP; Conselho Federal de Medicina ; 2020 .</mixed-citation>
				<element-citation publication-type="book">
					<person-group person-group-type="author">
						<name>
							<surname>Scheffer</surname>
							<given-names>M</given-names>
						</name>
						<role>coordenador</role>
					</person-group>
					<source>Demografia Médica no Brasil 2020</source>
					<publisher-loc>São Paulo</publisher-loc>
					<publisher-name>Departamento de Medicina Preventiva da Faculdade de Medicina da USP; Conselho Federal de Medicina</publisher-name>
					<year>2020</year>
				</element-citation>
			</ref>
			<ref id="B23">
				<label>23</label>
				<mixed-citation>23. Ramos LR , Mari JJ , Fontanella AT , Pizzol TSD , BertoldI AD , Mengue SS ; PNAUM Research Group . Nationwide use of psychotropic drugs for treatment of self-reported depression in the Brazilian urban adult population . Rev Bras Epidemiol . 2020 ; 23 : E200059 . <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/1980-549720200059">https://doi.org/10.1590/1980-549720200059</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ramos</surname>
							<given-names>LR</given-names>
						</name>
						<name>
							<surname>Mari</surname>
							<given-names>JJ</given-names>
						</name>
						<name>
							<surname>Fontanella</surname>
							<given-names>AT</given-names>
						</name>
						<name>
							<surname>Pizzol</surname>
							<given-names>TSD</given-names>
						</name>
						<name>
							<surname>BertoldI</surname>
							<given-names>AD</given-names>
						</name>
						<name>
							<surname>Mengue</surname>
							<given-names>SS</given-names>
						</name>
						<collab>PNAUM Research Group</collab>
					</person-group>
					<article-title>Nationwide use of psychotropic drugs for treatment of self-reported depression in the Brazilian urban adult population</article-title>
					<source>Rev Bras Epidemiol</source>
					<year>2020</year>
					<volume>23</volume>
					<elocation-id>E200059</elocation-id>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/1980-549720200059">https://doi.org/10.1590/1980-549720200059</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B24">
				<label>24</label>
				<mixed-citation>24. Valenstein M , Taylor KK , Austin K , Kales HC , McCarthy JF , Blow FC , et al . Benzodiazepine use among depressed patients treated in mental health settings . Am J Psychiatry 2004 ; 161 ( 4 ): 654 - 61 . <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1176/appi.ajp.161.4.654">https://doi.org/10.1176/appi.ajp.161.4.654</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Valenstein</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Taylor</surname>
							<given-names>KK</given-names>
						</name>
						<name>
							<surname>Austin</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Kales</surname>
							<given-names>HC</given-names>
						</name>
						<name>
							<surname>McCarthy</surname>
							<given-names>JF</given-names>
						</name>
						<name>
							<surname>Blow</surname>
							<given-names>FC</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Benzodiazepine use among depressed patients treated in mental health settings</article-title>
					<source>Am J Psychiatry</source>
					<year>2004</year>
					<volume>161</volume>
					<issue>4</issue>
					<fpage>654</fpage>
					<lpage>661</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1176/appi.ajp.161.4.654">https://doi.org/10.1176/appi.ajp.161.4.654</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B25">
				<label>25</label>
				<mixed-citation>25. Furukawa TA , Streiner DL , Young LT . Antidepressant and benzodiazepine for major depression . Cochrane Database Syst Rev . 2002 ;( 1 ): CD001026 . <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/14651858.CD001026">https://doi.org/10.1002/14651858.CD001026</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Furukawa</surname>
							<given-names>TA</given-names>
						</name>
						<name>
							<surname>Streiner</surname>
							<given-names>DL</given-names>
						</name>
						<name>
							<surname>Young</surname>
							<given-names>LT</given-names>
						</name>
					</person-group>
					<article-title>Antidepressant and benzodiazepine for major depression</article-title>
					<source>Cochrane Database Syst Rev</source>
					<year>2002</year>
					<issue>1</issue>
					<size units="pages">CD001026</size>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/14651858.CD001026">https://doi.org/10.1002/14651858.CD001026</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B26">
				<label>26</label>
				<mixed-citation>26. Bendtsen P , Hensing G , McKenzie L , Stridsman AK . Prescribing benzodiazepines: a critical incident study of a physician dilemma . Soc Sci Med 1999 ; 49 ( 4 ): 459 - 67 . <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/s0277-9536(99)00133-1">https://doi.org/10.1016/s0277-9536(99)00133-1</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bendtsen</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Hensing</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>McKenzie</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Stridsman</surname>
							<given-names>AK</given-names>
						</name>
					</person-group>
					<article-title>Prescribing benzodiazepines: a critical incident study of a physician dilemma</article-title>
					<source>Soc Sci Med</source>
					<year>1999</year>
					<volume>49</volume>
					<issue>4</issue>
					<fpage>459</fpage>
					<lpage>467</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/s0277-9536(99)00133-1">https://doi.org/10.1016/s0277-9536(99)00133-1</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B27">
				<label>27</label>
				<mixed-citation>27. Nastasy H , Ribeiro M , Marques ACPR . Associação Brasileira de Psiquiatria. Abuso e Dependência de Benzodiazepínicos . Projeto Diretrizes . 2008 .</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Nastasy</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Ribeiro</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Marques</surname>
							<given-names>ACPR</given-names>
						</name>
					</person-group>
					<article-title>Associação Brasileira de Psiquiatria. Abuso e Dependência de Benzodiazepínicos</article-title>
					<source>Projeto Diretrizes</source>
					<year>2008</year>
				</element-citation>
			</ref>
			<ref id="B28">
				<label>28</label>
				<mixed-citation>28. Gress T , Miller M , Meadows C III , Neitch SM . Benzodiazepine overuse in elders: defining the problem and potential solutions . Cureus . 2020 ; 12 ( 10 ): e11042 . <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7759/cureus.11042">https://doi.org/10.7759/cureus.11042</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gress</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Miller</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Meadows</surname>
							<given-names>C</given-names>
							<suffix>III</suffix>
						</name>
						<name>
							<surname>Neitch</surname>
							<given-names>SM</given-names>
						</name>
					</person-group>
					<article-title>Benzodiazepine overuse in elders: defining the problem and potential solutions</article-title>
					<source>Cureus</source>
					<year>2020</year>
					<volume>12</volume>
					<issue>10</issue>
					<elocation-id>e11042</elocation-id>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7759/cureus.11042">https://doi.org/10.7759/cureus.11042</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B29">
				<label>29</label>
				<mixed-citation>29. World Health Organization . Coronavirus disease 2019 (COVID 19): situation report, 51 . Geneva (CH) : WHO : 2020 [ cited 2020 Apr 2 ]. Available from: <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/331475/nCoVsitrep11Mar2020-eng.pdf?sequence=1&amp;isAllowed=y">https://apps.who.int/iris/bitstream/handle/10665/331475/nCoVsitrep11Mar2020-eng.pdf?sequence=1&amp;isAllowed=y</ext-link>
				</mixed-citation>
				<element-citation publication-type="webpage">
					<person-group person-group-type="author">
						<collab>World Health Organization</collab>
					</person-group>
					<source>Coronavirus disease 2019 (COVID 19): situation report, 51</source>
					<publisher-loc>Geneva (CH)</publisher-loc>
					<publisher-name>WHO</publisher-name>
					<year>2020</year>
					<date-in-citation content-type="cited-date">cited 2020 Apr 2</date-in-citation>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/331475/nCoVsitrep11Mar2020-eng.pdf?sequence=1&amp;isAllowed=y">https://apps.who.int/iris/bitstream/handle/10665/331475/nCoVsitrep11Mar2020-eng.pdf?sequence=1&amp;isAllowed=y</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B30">
				<label>30</label>
				<mixed-citation>30. Smith BJ , Lim MH . How the COVID-19 pandemic is focusing attention on loneliness and social isolation . Public Health Res Pract . 2020 ; 30 ; 30 ( 2 ): 3022008 . <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.17061/phrp3022008">https://doi.org/10.17061/phrp3022008</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Smith</surname>
							<given-names>BJ</given-names>
						</name>
						<name>
							<surname>Lim</surname>
							<given-names>MH</given-names>
						</name>
					</person-group>
					<article-title>How the COVID-19 pandemic is focusing attention on loneliness and social isolation</article-title>
					<source>Public Health Res Pract</source>
					<year>2020</year>
					<day>30</day>
					<volume>30</volume>
					<issue>2</issue>
					<size units="pages">3022008</size>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.17061/phrp3022008">https://doi.org/10.17061/phrp3022008</ext-link>
					</comment>
				</element-citation>
			</ref>
		</ref-list>
		<fn-group>
			<fn fn-type="financial-disclosure" id="fn2">
				<p><bold>Funding:</bold>
 <italic>Secretaria de Ciência e Tecnologia Insumos Estratégicos</italic> (SCTIE - Secretariat of Science and Technology Strategic Inputs) on behalf of the Ministry of Health (Process 25000.111834/2).</p>
			</fn>
		</fn-group>
	</back>
	<sub-article article-type="translation" id="TRpt" xml:lang="pt">
		<front-stub>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>Artigo Original</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Utilização de benzodiazepínicos em idosos brasileiros: um estudo de base populacional</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-9307-4337</contrib-id>
					<name>
						<surname>Freire</surname>
						<given-names>Marina de Borba Oliveira</given-names>
					</name>
					<xref ref-type="aff" rid="aff9002"><sup>I</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-2917-7320</contrib-id>
					<name>
						<surname>Da Silva</surname>
						<given-names>Bruna Gonçalves Cordeiro</given-names>
					</name>
					<xref ref-type="aff" rid="aff2002"><sup>II</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-4680-3197</contrib-id>
					<name>
						<surname>Bertoldi</surname>
						<given-names>Andréa Dâmaso</given-names>
					</name>
					<xref ref-type="aff" rid="aff2002"><sup>II</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-0455-9429</contrib-id>
					<name>
						<surname>Fontanella</surname>
						<given-names>Andréia Turmina</given-names>
					</name>
					<xref ref-type="aff" rid="aff3002"><sup>III</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-3349-8541</contrib-id>
					<name>
						<surname>Mengue</surname>
						<given-names>Sotero Serrate</given-names>
					</name>
					<xref ref-type="aff" rid="aff3002"><sup>III</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-3143-8315</contrib-id>
					<name>
						<surname>Ramos</surname>
						<given-names>Luiz Roberto</given-names>
					</name>
					<xref ref-type="aff" rid="aff4002"><sup>IV</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-6180-7527</contrib-id>
					<name>
						<surname>Tavares</surname>
						<given-names>Noemia Urruth Leão</given-names>
					</name>
					<xref ref-type="aff" rid="aff5002"><sup>V</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-7566-7745</contrib-id>
					<name>
						<surname>Pizzol</surname>
						<given-names>Tatiane da Silva Dal</given-names>
					</name>
					<xref ref-type="aff" rid="aff6002"><sup>VI</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-4502-8467</contrib-id>
					<name>
						<surname>Arrais</surname>
						<given-names>Paulo Sérgio Dourado</given-names>
					</name>
					<xref ref-type="aff" rid="aff7002"><sup>VII</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-4319-9318</contrib-id>
					<name>
						<surname>Farias</surname>
						<given-names>Mareni Rocha</given-names>
					</name>
					<xref ref-type="aff" rid="aff8002"><sup>VIII</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-6245-7522</contrib-id>
					<name>
						<surname>Luiza</surname>
						<given-names>Vera Lucia</given-names>
					</name>
					<xref ref-type="aff" rid="aff9002"><sup>I</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-2400-536X</contrib-id>
					<name>
						<surname>Oliveira</surname>
						<given-names>Maria Auxiliadora</given-names>
					</name>
					<xref ref-type="aff" rid="aff9002"><sup>I</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-2996-9427</contrib-id>
					<name>
						<surname>Menezes</surname>
						<given-names>Ana Maria Baptista</given-names>
					</name>
					<xref ref-type="aff" rid="aff2002"><sup>II</sup></xref>
				</contrib>
			</contrib-group>
			<aff id="aff1002">
				<label>I</label>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Universidade Federal de Pelotas. Faculdade de Medicina. Programa de Pós-Graduação em Epidemiologia. Pelotas, RS, Brasil </institution>
			</aff>
			<aff id="aff2002">
				<label>II</label>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Universidade Federal de Pelotas. Faculdade de Medicina. Departamento de Medicina Social. Pelotas, RS, Brasil </institution>
			</aff>
			<aff id="aff3002">
				<label>III</label>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Universidade Federal do Rio Grande do Sul. Faculdade de Medicina. Programa de Pós-Graduação em Epidemiologia. Porto Alegre, RS, Brasil </institution>
			</aff>
			<aff id="aff4002">
				<label>IV</label>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Universidade Federal de São Paulo. Escola Paulista de Medicina. Departamento de Medicina Preventiva. São Paulo, SP, Brasil </institution>
			</aff>
			<aff id="aff5002">
				<label>V</label>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Universidade de Brasília. Faculdade de Ciências da Saúde. Departamento de Farmácia. Brasília, DF, Brasil </institution>
			</aff>
			<aff id="aff6002">
				<label>VI</label>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Universidade Federal do Rio Grande do Sul. Faculdade de Farmácia. Departamento de Produção e Controle de Medicamentos. Porto Alegre, RS, Brasil </institution>
			</aff>
			<aff id="aff7002">
				<label>VII</label>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Universidade Federal do Ceará. Faculdade de Farmácia, Odontologia e Enfermagem. Departamento de Farmácia. Fortaleza, CE, Brasil </institution>
			</aff>
			<aff id="aff8002">
				<label>VIII</label>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Universidade Federal de Santa Catarina. Centro de Ciências da Saúde. Departamento de Ciências Farmacêuticas. Florianópolis, SC, Brasil </institution>
			</aff>
			<aff id="aff9002">
				<label>I</label>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Departamento de Política de Medicamentos e Assistência Farmacêutica. Rio de Janeiro, RJ, Brasil </institution>
			</aff>
			<author-notes>
				<corresp id="c01002">Correspondência: Marina de Borba Oliveira Freire Rua Marechal Deodoro, 1.160 96020-220 Pelotas, RS, Brasil E-mail: deborbamarina@gmail.com</corresp>
				<fn fn-type="con">
					<p><bold>Contribuição dos Autores:</bold> Concepção e planejamento do estudo: MBOF, BGCS, ADB, AMBM. Análise e interpretação dos dados: MBOF, BGCS, ADB, AMBM. Elaboração ou revisão do manuscrito: MBOF, BGCS, ADB, ATF, SSM, LRR, NULT, TSDP, PSDA, MRF, VLL, MAO, AMBM. Aprovação da versão final: MBOF, BGCS, ADB, ATF, SSM, LRR, NULT, TSDP, PSDA, MRF, VLL, MAO, AMBM. Responsabilidade pública pelo conteúdo do artigo: MBOF, BGCS, ADB, ATF, SSM, LRR, NULT, TSDP, PSDA, MRF, VLL, MAO, AMBM.</p>
				</fn>
				<fn fn-type="conflict">
					<p><bold>Conflito de Interesses:</bold> Os autores declaram não haver conflito de interesses.</p>
				</fn>
			</author-notes>
			<abstract>
				<title>RESUMO</title>
				<sec>
					<title>OBJETIVO</title>
					<p>Avaliar a utilização de benzodiazepínicos (BZD) em idosos brasileiros,a partir de dados da Pesquisa Nacional de Acesso, Utilização e Promoção do Uso Racional de Medicamentos (PNAUM).</p>
				</sec>
				<sec>
					<title>MÉTODOS</title>
					<p>A PNAUM é um estudo transversal, conduzido entre 2013 e 2014, com representatividade da população urbana brasileira. No presente estudo, foram incluídos indivíduos com 60 anos ou mais (n = 9.019). Foi calculada a prevalência de utilização de BZD nos 15 dias anteriores à coleta dos dados da pesquisa, geral e segundo as variáveis independentes, por meio de análise bruta e ajustada, utilizando modelo hierárquico de regressão de Poisson. A coleta de dados foi realizada por meio de entrevista domiciliar.</p>
				</sec>
				<sec>
					<title>RESULTADOS</title>
					<p>A prevalência de utilização de BZD em idosos foi de 9,3% (IC95%: 8,3–10,4). Após análise ajustada, foram associados à maior utilização de BZD: sexo feminino (RP = 1,88; IC95%: 1,52–2,32), depressão (RP = 5,31; IC95%: 4,41–6,38), multimorbidade (RP = 1,44; IC95%: 1,20–1,73), visita à emergência ou internação hospitalar nos últimos 12 meses (RP = 1,42; IC95%: 1,18–1,70), polifarmácia (RP = 1,26; IC95%: 1,01–1,57) e autopercepção de saúde ruim ou muito ruim (RP = 4,16; IC95%: 2,10–8,22). A utilização foi menor na região Norte (RP = 0,18; IC95%: 0,13–0,27) e em indivíduos que relataram consumo abusivo de álcool no último mês (RP = 0,42; IC95%: 0,19–0,94).</p>
				</sec>
				<sec>
					<title>CONCLUSÃO</title>
					<p>Apesar das recomendações contrárias ao uso, os resultados demonstraram elevada prevalência de utilização de BZD em idosos, particularmente naqueles que apresentam depressão, além de amplas diferenças em relação às regiões do país e ao sexo do indivíduo.</p>
				</sec>
			</abstract>
			<kwd-group xml:lang="pt">
				<kwd>Idoso</kwd>
				<kwd>Uso de Medicamentos</kwd>
				<kwd>Benzodiazepinas</kwd>
				<kwd>Fatores de Risco</kwd>
				<kwd>Estudos Transversais</kwd>
			</kwd-group>
		</front-stub>
		<body>
			<sec sec-type="intro">
				<title>INTRODUÇÃO</title>
				<p>Os primeiros benzodiazepínicos (BZD) foram sintetizados na década de 1950 <sup><xref ref-type="bibr" rid="B1">1</xref></sup> e alcançaram grande popularidade nos anos seguintes devido a sua comprovada eficácia no tratamento da ansiedade, insônia, agressividade e convulsões <sup><xref ref-type="bibr" rid="B2">2</xref></sup> , além de uso adjuvante em outras condições clínicas, como relaxamento muscular e analgesia <sup><xref ref-type="bibr" rid="B3">3</xref></sup> . A baixa incidência de depressão respiratória com BZD ingeridos por via oral propiciou uma sensação de segurança e contribuiu para tornar a classe uma das mais prescritas ao redor do mundo <sup><xref ref-type="bibr" rid="B2">2</xref></sup> .</p>
				<p>Entretanto, o uso prolongado mostrou-se associado a extensa gama de eventos adversos, aliado à fraca evidência de benefício em longo prazo <sup><xref ref-type="bibr" rid="B4">4</xref></sup> . Os eventos adversos documentados com a utilização de BZD incluem demência, declínio cognitivo, transtornos psicomotores, sonolência diurna, acidentes de carro, tolerância e dependência <sup><xref ref-type="bibr" rid="B3">3</xref></sup> , além de maior incidência de fraturas e quedas, restrição da mobilidade e redução da participação social em idosos <sup><xref ref-type="bibr" rid="B5">5</xref></sup> . Por isso, os BZD são classificados como medicamentos potencialmente inapropriados, cuja prescrição deve ser evitada em idosos <sup><xref ref-type="bibr" rid="B6">6</xref></sup> , porém, apesar dessa recomendação, a literatura aponta o aumento da utilização de BZD com o aumento da idade <sup><xref ref-type="bibr" rid="B7">7</xref></sup> , dado preocupante considerando o maior risco de eventos adversos associado às modificações da farmacodinâmica e farmacocinética induzidas pela idade e polifarmácia <sup><xref ref-type="bibr" rid="B8">8</xref></sup> .</p>
				<p>Nesse cenário, o Ministério da Saúde, por meio do Comitê Nacional para a Promoção do Uso Racional de Medicamentos, lançou em 2019 a publicação intitulada “Uso de Medicamentos e Medicalização da Vida: Recomendações e Estratégias”, com objetivo de promover o uso racional de medicamentos por meio do estímulo à educação, informação, regulação e pesquisa; a publicação destacou a necessidade de restringir a prescrição de BZD para indivíduos com 60 anos ou mais <sup><xref ref-type="bibr" rid="B9">9</xref></sup> .</p>
				<p>Até o momento, não foram encontrados estudos com representatividade nacional que tenham avaliado a utilização de BZD em idosos. O presente estudo tem como objetivo preencher essa lacuna na literatura, avaliando a prevalência de utilização de BZD em idosos brasileiros e sua distribuição, segundo variáveis sociodemográficas, comportamentais e relacionadas à saúde, a partir de dados da Pesquisa Nacional de Acesso, Utilização e Promoção do Uso Racional de Medicamentos (PNAUM).</p>
			</sec>
			<sec sec-type="methods">
				<title>MÉTODOS</title>
				<p>A PNAUM foi um estudo transversal, de base populacional, conduzido entre setembro de 2013 e fevereiro de 2014, que incluiu indivíduos de todas as idades, residentes na zona urbana do território brasileiro (n = 41.433). O processo de amostragem foi realizado em três estágios (municípios, setores censitários e domicílios), seguido por processo de pós-estratificação por região, sexo e idade, garantindo a representatividade da população brasileira. A coleta de dados foi realizada por meio de entrevista domiciliar, face a face, com o registro dos dados em tablet com software específico para os questionários da pesquisa. As informações dos entrevistados incapazes de se comunicar foram obtidas por meio de informante substituto. Informações adicionais encontram-se disponíveis em publicação anterior <sup><xref ref-type="bibr" rid="B10">10</xref></sup> .</p>
				<p>No presente estudo, foram analisados os dados referentes à população idosa (60 anos ou mais) entrevistada durante o inquérito (n = 9.019).</p>
				<p>A variável dependente analisada foi a utilização de BZD nos 15 dias anteriores à coleta dos dados da pesquisa, construída com informações provenientes de duas variáveis investigadas: 1) medicamentos de uso crônico, em que foram avaliados todos os medicamentos referidos pelo entrevistado como de uso corrente para o tratamento de determinada doença crônica; e 2) medicamentos de uso eventual, a partir da seguinte pergunta: “Nos últimos 15 dias, o(a) Sr.(a) tomou algum remédio para dormir ou para os nervos?”. Quando a resposta era positiva, foi feita uma pergunta adicional: “Quanto tempo vai durar o tratamento?” (tomou apenas uma vez; até melhorar/curar; não vai mais tomar; sempre que voltarem os sintomas; para sempre).</p>
				<p>A fim de garantir melhor qualidade da informação, foi solicitado ao indivíduo que mostrasse a(s) caixa(s) ou a(s) receita(s) do(s) medicamento(s).</p>
				<p>Foram considerados BZD os medicamentos classificados segundo o <italic>Anatomical Therapeutic Chemical Index</italic> (ATC Index), desenvolvido pelo <italic>World Health Organization Collaboration Center for Drugs Statistic Methodology</italic>
 <sup><xref ref-type="bibr" rid="B11">11</xref></sup> , sob os códigos N05BA (derivados BZD ansiolíticos) e N05CD (derivados BZD hipnóticos) comercializados no Brasil, além do clonazepam, classificado como anticonvulsivante sob código N03AE01. Foram coletadas ainda informações quanto à utilização de fármacos relacionados aos BZD comercializados no Brasil (zolpidem e zopiclone), sob o código N05CF <sup><xref ref-type="bibr" rid="B11">11</xref></sup> , embora esses medicamentos não tenham sido incluídos no desfecho principal por não pertencerem à classe dos BZD.</p>
				<p>As variáveis independentes englobaram fatores sociodemográficos, comportamentais e relacionados à saúde:</p>
				<p>a.Sociodemográficos: região (Norte; Nordeste; Centro-Oeste; Sudeste; Sul); sexo (masculino; feminino); idade (anos: 60 a 69; 70 a 79; 80 ou mais); cor da pele autorreferida (branca; preta; parda; amarela; indígena); situação conjugal (sem companheiro[a]; com companheiro[a]); escolaridade (anos de estudo: 0 a 4; 5 a 8; 9 a 11; 12 ou mais); classificação econômica (A-B [mais ricos]; C; D; E [mais pobres]), de acordo com a classificação da Associação Brasileira de Empresas de Pesquisa (ABEP) <sup><xref ref-type="bibr" rid="B12">12</xref></sup> ;</p>
				<p>b.Comportamentais: tabagismo (tabagista atual; ex-tabagista; não tabagista); consumo abusivo de álcool no último mês (sim; não), definido como abusivo o consumo de quatro ou mais doses de bebida alcoólica (mulher) ou cinco ou mais doses (homem), em uma única ocasião, pelo menos uma vez no último mês, sendo uma dose de bebida alcoólica equivalente a uma lata de cerveja, uma taça de vinho ou uma dose de cachaça, whisky ou qualquer outra bebida alcoólica destilada;</p>
				<p>c.Relacionados à saúde: plano de saúde (sim; não); depressão (sim; não), avaliada por meio da pergunta: “Algum médico já lhe disse que o(a) Sr.(a) tem depressão?”; multimorbidade (sim; não), considerando-se como multimorbidade a presença de duas doenças crônicas ou mais. Foram incluídas as doenças: pressão alta, diabetes, doença cardíaca, colesterol alto, isquemia ou derrame cerebral, asma, doença pulmonar obstrutiva crônica (enfisema ou bronquite crônica) e doença reumatológica. A presença ou não dessas doenças foi avaliada por meio da pergunta: “Algum médico já lhe disse que o(a) Sr.(a) tem [doença]?”; visita à emergência ou internação hospitalar nos últimos 12 meses (sim; não); polifarmácia (sim; não), considerando-se como polifarmácia a utilização atual de cinco medicamentos ou mais (excluindo os BZD), incluindo homeopatia, fórmulas feitas em farmácia de manipulação, florais, vitaminas e fitoterápicos; e autopercepção de saúde (muito boa; boa; regular; ruim/muito ruim).</p>
				<p>Foi realizada análise descritiva das variáveis independentes para caracterização da amostra, sendo calculadas as proporções e respectivos intervalos de confiança de 95%. Foi calculada a prevalência de utilização de BZD nos 15 dias anteriores à coleta dos dados, com seu respectivo intervalo de confiança de 95%, geral e conforme as variáveis independentes. Com o uso dos pesos pós-estratificação, perde-se a relação direta entre o número de observações e os percentuais, assim, o número de observações amostrais (n) foi mantido somente nos títulos das tabelas. Foi empregada regressão de Poisson com variância robusta, para obtenção das razões de prevalência, brutas e ajustadas. Na análise ajustada, seguiu-se modelo hierárquico em cinco níveis, construído com base na literatura. O primeiro nível incluiu as variáveis região do país, sexo, idade e cor da pele; no segundo nível constou as variáveis ABEP, escolaridade e situação conjugal; o terceiro nível, por sua vez, integrou as variáveis plano de saúde, tabagismo, depressão e multimorbidade; no quarto nível, a variável visita à emergência ou internação hospitalar nos últimos 12 meses; e o quinto e último nível abarca as variáveis polifarmácia, consumo abusivo de álcool no último mês e autopercepção de saúde. As variáveis foram ajustadas para as do mesmo nível e do(s) nível(is) superior(es); foi utilizado o modo de seleção para trás, sendo mantidas no modelo final aquelas com valor de p &lt; 0,20. Considerou-se nível de significância de 5%. Os dados foram analisados com o programa Stata versão 15.1 (StataCorp, College Station, Texas, USA).</p>
				<p>A PNAUM foi aprovada pela Comissão Nacional de Ética em Pesquisa (Protocolo 18947013.6.0000.0008) e pelo Comitê de Ética em Pesquisa da Universidade Federal do Rio Grande do Sul (Protocolo 19997). As entrevistas foram realizadas após leitura do termo de consentimento livre e esclarecido e assinatura do entrevistado ou seu responsável legal.</p>
			</sec>
			<sec sec-type="results">
				<title>RESULTADOS</title>
				<p>Foram incluídos neste estudo 9.019 indivíduos que, após o ajuste por região, sexo e idade, passaram a representar os aproximadamente 23 milhões de idosos residentes na zona urbana do país.</p>
				<p>Predominaram mulheres (57,7%), indivíduos com idade entre 60 e 69 anos (52,3%), de cor de pele branca (52,8%), pertencentes à classe econômica C (54,7%), que viviam com companheiro (55,8%) e residiam na região Sudeste (52,5%). Do total, 9,5% e 41,5% apresentavam depressão e multimorbidade, respectivamente, e 21,8% eram usuários de polifarmácia. Cerca de 4% relatou consumo abusivo de álcool no último mês, com ampla diferença entre os sexos (mulheres: 1%; IC95% 0,7–1,5 versus homens: 8,3%; IC95% 7,0–9,8). Quase metade da amostra apresentava autopercepção de saúde boa ( <xref ref-type="table" rid="t1002">Tabela 1</xref> ).</p>
				<p>
					<table-wrap id="t1002">
						<label>Tabela 1</label>
						<caption>
							<title>Descrição da amostra, segundo variáveis sociodemográficas, comportamentais e relacionadas à saúde. PNAUM, 2014 (n = 9.019).</title>
						</caption>
						<table frame="hsides" rules="groups">
							<colgroup>
								<col/>
								<col/>
								<col/>
							</colgroup>
							<thead>
								<tr>
									<th align="left">Variáveis</th>
									<th>% <sup>a</sup></th>
									<th>IC95%</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td>Região</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Norte</td>
									<td align="center">4,8</td>
									<td align="center">3,8–6,1</td>
								</tr>
								<tr>
									<td>Nordeste</td>
									<td align="center">21,2</td>
									<td align="center">17,2–25,8</td>
								</tr>
								<tr>
									<td>Centro-Oeste</td>
									<td align="center">6,8</td>
									<td align="center">5,4–8,5</td>
								</tr>
								<tr>
									<td>Sudeste</td>
									<td align="center">52,5</td>
									<td align="center">46,5–58,4</td>
								</tr>
								<tr>
									<td>Sul</td>
									<td align="center">14,7</td>
									<td align="center">11,8–18,1</td>
								</tr>
								<tr>
									<td>Sexo</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Masculino</td>
									<td align="center">42,2</td>
									<td align="center">40,7–43,8</td>
								</tr>
								<tr>
									<td>Feminino</td>
									<td align="center">57,7</td>
									<td align="center">56,2–59,3</td>
								</tr>
								<tr>
									<td>Idade</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>60–69 anos</td>
									<td align="center">52,3</td>
									<td align="center">50,7–53,9</td>
								</tr>
								<tr>
									<td>70–79 anos</td>
									<td align="center">32,4</td>
									<td align="center">31,0–33,9</td>
								</tr>
								<tr>
									<td>80 anos ou mais</td>
									<td align="center">15,2</td>
									<td align="center">14,1–16,4</td>
								</tr>
								<tr>
									<td>Cor da pele</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Branca</td>
									<td align="center">52,8</td>
									<td align="center">49,8–55,8</td>
								</tr>
								<tr>
									<td>Preta</td>
									<td align="center">9,7</td>
									<td align="center">8,5–11,0</td>
								</tr>
								<tr>
									<td>Parda</td>
									<td align="center">36,0</td>
									<td align="center">33,4–38,7</td>
								</tr>
								<tr>
									<td>Amarela</td>
									<td align="center">1,2</td>
									<td align="center">0,9–1,6</td>
								</tr>
								<tr>
									<td>Indígena</td>
									<td align="center">0,3</td>
									<td align="center">0,2–0,4</td>
								</tr>
								<tr>
									<td>ABEP</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>A–B</td>
									<td align="center">21,6</td>
									<td align="center">19,5–23,9</td>
								</tr>
								<tr>
									<td>C</td>
									<td align="center">54,7</td>
									<td align="center">52,7–56,6</td>
								</tr>
								<tr>
									<td>D</td>
									<td align="center">19,0</td>
									<td align="center">17,1–21,1</td>
								</tr>
								<tr>
									<td>E</td>
									<td align="center">4,6</td>
									<td align="center">4,0–5,5</td>
								</tr>
								<tr>
									<td>Escolaridade</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>0–4 anos</td>
									<td align="center">38,9</td>
									<td align="center">36,8–40,9</td>
								</tr>
								<tr>
									<td>5–8 anos</td>
									<td align="center">20,1</td>
									<td align="center">18,8–21,4</td>
								</tr>
								<tr>
									<td>9–11 anos</td>
									<td align="center">30,1</td>
									<td align="center">28,5–31,7</td>
								</tr>
								<tr>
									<td>12 anos ou mais</td>
									<td align="center">10,9</td>
									<td align="center">9,7–12,2</td>
								</tr>
								<tr>
									<td>Situação conjugal</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sem companheiro</td>
									<td align="center">44,2</td>
									<td align="center">42,3–46,1</td>
								</tr>
								<tr>
									<td>Com companheiro</td>
									<td align="center">55,8</td>
									<td align="center">53,9–57,6</td>
								</tr>
								<tr>
									<td>Plano de saúde</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">73,0</td>
									<td align="center">70,1–75,6</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">27,0</td>
									<td align="center">24,3–29,9</td>
								</tr>
								<tr>
									<td>Tabagismo</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Nunca fumou</td>
									<td align="center">62,5</td>
									<td align="center">60,3–64,7</td>
								</tr>
								<tr>
									<td>Ex-tabagista</td>
									<td align="center">26,9</td>
									<td align="center">25,1–28,8</td>
								</tr>
								<tr>
									<td>Tabagista atual</td>
									<td align="center">10,6</td>
									<td align="center">9,6–11,6</td>
								</tr>
								<tr>
									<td>Depressão</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">90,5</td>
									<td align="center">89,4–91,4</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">9,5</td>
									<td align="center">8,6–10,6</td>
								</tr>
								<tr>
									<td>Multimorbidade</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">58,5</td>
									<td align="center">56,5–60,5</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">41,5</td>
									<td align="center">39,5–43,5</td>
								</tr>
								<tr>
									<td>Visita à emergência ou internação hospitalar nos últimos 12 meses</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">78,7</td>
									<td align="center">77,2–80,2</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">21,3</td>
									<td align="center">19,8–22,8</td>
								</tr>
								<tr>
									<td>Polifarmácia</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">78,2</td>
									<td align="center">76,5–79,8</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">21,8</td>
									<td align="center">20,2–23,5</td>
								</tr>
								<tr>
									<td>Consumo abusivo de álcool do último mês</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">95,9</td>
									<td align="center">95,2–96,5</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">4,1</td>
									<td align="center">3,5–4,8</td>
								</tr>
								<tr>
									<td>Autopercepção de saúde</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Muito boa</td>
									<td align="center">8,0</td>
									<td align="center">7,2–8,9</td>
								</tr>
								<tr>
									<td>Boa</td>
									<td align="center">48,9</td>
									<td align="center">47,0–50,7</td>
								</tr>
								<tr>
									<td>Regular</td>
									<td align="center">36,0</td>
									<td align="center">34,4–37,5</td>
								</tr>
								<tr>
									<td>Ruim/Muito ruim</td>
									<td align="center">7,1</td>
									<td align="center">6,4–7,9</td>
								</tr>
							</tbody>
						</table>
						<table-wrap-foot>
							<fn id="TFN1002">
								<p><sup>a</sup> Percentuais ajustados por pesos amostrais e por pós-estratificação, segundo idade e sexo.</p>
							</fn>
						</table-wrap-foot>
					</table-wrap>
				</p>
				<p>A prevalência de utilização de BZD em idosos nos 15 dias anteriores à coleta dos dados da pesquisa foi de 9,3% (IC95% 8,3–10,4). Considerando o total de usuários de BZD, 59,3% (IC95% 54,0–64,4%) referiram uso eventual; ainda assim, desses, 36,8% (IC95% 30,8–43,1) responderam que o tratamento iria durar “para sempre” e 27,2% (IC95% 21,9–33,2) que iriam tomar o medicamento “sempre que voltassem os sintomas”. Somente 0,7% (IC95% 0,2–2,4) referiu que não iria mais tomar o medicamento.</p>
				<p>Considerando o total de BZD, os que apresentaram maior proporção de utilização foram clonazepam (41,3%; IC95% 36,7–46,0), diazepam (22,2%; IC95% 18,2–26,9), bromazepam (14,5%; IC95% 11,5–18,2) e alprazolam (9,6%; IC95% 7,3–12,5) ( <xref ref-type="fig" rid="f01002">Figura 1</xref> ). Esse padrão manteve-se semelhante em todas as regiões do país. Em relação aos fármacos relacionados aos BZD, a prevalência de utilização de zolpidem em idosos foi de 0,1% (IC95% 0,06–0,2).</p>
				<p>
					<fig id="f01002">
						<label>Figura 1</label>
						<caption>
							<title>Proporção de benzodiazepínicos utilizados por idosos brasileiros nos 15 dias anteriores à coleta dos dados da pesquisa. PNAUM, 2014 (n = 699).</title>
						</caption>
						<graphic xlink:href="1518-8787-rsp-56-10-gf01-pt.tif"/>
					</fig>
				</p>
				<p>A <xref ref-type="fig" rid="f02002">Figura 2</xref> demonstra a prevalência de utilização de BZD em idosos por região do país, estratificada por sexo. Percebe-se que a prevalência de utilização de BZD é consistentemente maior em mulheres, embora com importantes diferenças regionais: enquanto na Região Norte a diferença entre os sexos é pequena, não alcançando significância estatística, nas regiões Sul e Centro-Oeste a variação é ampla, atingindo prevalências aproximadamente duas e três vezes maior em mulheres do que em homens, respectivamente.</p>
				<p>
					<fig id="f02002">
						<label>Figura 2</label>
						<caption>
							<title>Utilização de benzodiazepínicos em idosos brasileiros nos 15 dias anteriores à coleta dos dados da pesquisa, segundo região do país e sexo. PNAUM, 2014 (n = 9.019).</title>
						</caption>
						<graphic xlink:href="1518-8787-rsp-56-10-gf02-pt.tif"/>
					</fig>
				</p>
				<p>As maiores prevalências de utilização de BZD foram encontradas nas seguintes categorias: sexo feminino, regiões Sul e Sudeste, 70 anos de idade ou mais, cor da pele branca, viver sem companheiro, possuir plano de saúde, ter depressão ou multimorbidade, visita à emergência ou internação hospitalar nos últimos 12 meses, polifarmácia, não relatar consumo abusivo de álcool no último mês e autopercepção de saúde ruim ou muito ruim ( <xref ref-type="table" rid="t2002">Tabela 2</xref> ).</p>
				<p>
					<table-wrap id="t2002">
						<label>Tabela 2</label>
						<caption>
							<title>Prevalência e razões de prevalência brutas para utilização de benzodiazepínicos em idosos brasileiros nos 15 dias anteriores à coleta dos dados da pesquisa, segundo variáveis sociodemográficas, comportamentais e relacionadas à saúde. PNAUM, 2014 (n = 9.019).</title>
						</caption>
						<table frame="hsides" rules="groups">
							<colgroup>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
							</colgroup>
							<thead>
								<tr>
									<th align="left">Variável</th>
									<th>Prevalência (%) <sup>a</sup></th>
									<th>IC95%</th>
									<th>RP bruta</th>
									<th>IC95%</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td>Região</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">p &lt; 0,001 <sup>b</sup></td>
								</tr>
								<tr>
									<td>Norte</td>
									<td align="center">1,8</td>
									<td align="center">1,3–2,6</td>
									<td align="center">0,18</td>
									<td align="center">0,12–0,26</td>
								</tr>
								<tr>
									<td>Nordeste</td>
									<td align="center">8,2</td>
									<td align="center">7,1–9,7</td>
									<td align="center">0,81</td>
									<td align="center">0,66–0,99</td>
								</tr>
								<tr>
									<td>Centro-Oeste</td>
									<td align="center">6,1</td>
									<td align="center">4,8–7,6</td>
									<td align="center">0,60</td>
									<td align="center">0,46–0,77</td>
								</tr>
								<tr>
									<td>Sudeste</td>
									<td align="center">10,2</td>
									<td align="center">8,5–12,2</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sul</td>
									<td align="center">11,5</td>
									<td align="center">9,6–13,7</td>
									<td align="center">1,13</td>
									<td align="center">0,92–1,38</td>
								</tr>
								<tr>
									<td>Sexo</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">p &lt; 0,001 <sup>b</sup></td>
								</tr>
								<tr>
									<td>Masculino</td>
									<td align="center">6,0</td>
									<td align="center">5,0–7,1</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Feminino</td>
									<td align="center">11,8</td>
									<td align="center">10,3–13,4</td>
									<td align="center">1,97</td>
									<td align="center">1,60–2,43</td>
								</tr>
								<tr>
									<td>Idade</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">p = 0,003 <sup>b</sup></td>
								</tr>
								<tr>
									<td>60–69 anos</td>
									<td align="center">7,9</td>
									<td align="center">6,8–9,2</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>70–79 anos</td>
									<td align="center">11,0</td>
									<td align="center">9,3–12,9</td>
									<td align="center">1,39</td>
									<td align="center">1,13–1,71</td>
								</tr>
								<tr>
									<td>80 anos ou mais</td>
									<td align="center">10,6</td>
									<td align="center">8,3–13,3</td>
									<td align="center">1,34</td>
									<td align="center">1,04–1,73</td>
								</tr>
								<tr>
									<td>Cor da pele <sup>d</sup></td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">p = 0,004 <sup>b</sup></td>
								</tr>
								<tr>
									<td>Branca</td>
									<td align="center">11,1</td>
									<td align="center">9,8–12,4</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Preta</td>
									<td align="center">7,8</td>
									<td align="center">5,4–11,2</td>
									<td align="center">0,71</td>
									<td align="center">0,50–1,02</td>
								</tr>
								<tr>
									<td>Parda</td>
									<td align="center">8,0</td>
									<td align="center">6,7–9,5</td>
									<td align="center">0,72</td>
									<td align="center">0,59–0,89</td>
								</tr>
								<tr>
									<td>ABEP</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">p = 0,867 <sup>b</sup></td>
								</tr>
								<tr>
									<td>A–B</td>
									<td align="center">8,6</td>
									<td align="center">7,2–9,3</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>C</td>
									<td align="center">9,5</td>
									<td align="center">8,4–10,8</td>
									<td align="center">1,11</td>
									<td align="center">0,87–1,40</td>
								</tr>
								<tr>
									<td>D</td>
									<td align="center">9,4</td>
									<td align="center">7,4–12,0</td>
									<td align="center">1,09</td>
									<td align="center">0,82–1,44</td>
								</tr>
								<tr>
									<td>E</td>
									<td align="center">8,8</td>
									<td align="center">5,7–13,4</td>
									<td align="center">1,02</td>
									<td align="center">0,62–1,67</td>
								</tr>
								<tr>
									<td>Escolaridade</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">p = 0,185 <sup>b</sup></td>
								</tr>
								<tr>
									<td>0–4 anos</td>
									<td align="center">10,4</td>
									<td align="center">8,8–9,1</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>5–8 anos</td>
									<td align="center">8,2</td>
									<td align="center">6,7–10,2</td>
									<td align="center">0,79</td>
									<td align="center">0,62–1,01</td>
								</tr>
								<tr>
									<td>9–11 anos</td>
									<td align="center">8,7</td>
									<td align="center">6,9–10,9</td>
									<td align="center">0,84</td>
									<td align="center">0,66–1,07</td>
								</tr>
								<tr>
									<td>12 anos ou mais</td>
									<td align="center">8,4</td>
									<td align="center">6,3–10,9</td>
									<td align="center">0,80</td>
									<td align="center">0,59–1,10</td>
								</tr>
								<tr>
									<td>Situação conjugal</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">p &lt; 0,001 <sup>b</sup></td>
								</tr>
								<tr>
									<td>Sem companheiro</td>
									<td align="center">11,5</td>
									<td align="center">9,8–13,4</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Com companheiro</td>
									<td align="center">7,9</td>
									<td align="center">6,9–9,1</td>
									<td align="center">0,69</td>
									<td align="center">0,57–0,83</td>
								</tr>
								<tr>
									<td>Plano de saúde</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">p = 0,005 <sup>b</sup></td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">8,5</td>
									<td align="center">7,5–9.6</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">11,5</td>
									<td align="center">9,4–13,9</td>
									<td align="center">1,34</td>
									<td align="center">1,09–1,64</td>
								</tr>
								<tr>
									<td>Tabagismo</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">p = 0,450 <sup>a</sup></td>
								</tr>
								<tr>
									<td>Nunca fumou</td>
									<td align="center">9,3</td>
									<td align="center">8,0–10,8</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Ex-tabagista</td>
									<td align="center">8,1</td>
									<td align="center">6,4–10,1</td>
									<td align="center">0,87</td>
									<td align="center">0,68–1,11</td>
								</tr>
								<tr>
									<td>Tabagista atual</td>
									<td align="center">9,8</td>
									<td align="center">7,6–12,7</td>
									<td align="center">1,05</td>
									<td align="center">0,79–1,41</td>
								</tr>
								<tr>
									<td>Depressão</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">p &lt; 0,001 <sup>b</sup></td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">6,0</td>
									<td align="center">5,3–10,0</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">39,9</td>
									<td align="center">34,7–45,4</td>
									<td align="center">6,59</td>
									<td align="center">5,57–7,80</td>
								</tr>
								<tr>
									<td>Multimorbidade</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">p &lt; 0,001 <sup>b</sup></td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">6,2</td>
									<td align="center">5,3–7,3</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">13,6</td>
									<td align="center">11,9–15,6</td>
									<td align="center">2,88</td>
									<td align="center">2,37–3,50</td>
								</tr>
								<tr>
									<td>Visita à emergência ou internação hospitalar nos últimos 12 meses</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">p &lt; 0,001 <sup>b</sup></td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">7,7</td>
									<td align="center">6,8–8,8</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">15,1</td>
									<td align="center">12,8–17,8</td>
									<td align="center">1,95</td>
									<td align="center">1,60–2,38</td>
								</tr>
								<tr>
									<td>Polifarmácia</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">p &lt; 0,001 <sup>b</sup></td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">6,8</td>
									<td align="center">6,0–7,8</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">18,2</td>
									<td align="center">15,4–21,3</td>
									<td align="center">2,65</td>
									<td align="center">2,21–3,19</td>
								</tr>
								<tr>
									<td>Consumo abusivo de álcool do último mês</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">p &lt; 0,001 <sup>b</sup></td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">9,4</td>
									<td align="center">8,3–10,7</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">2,3</td>
									<td align="center">1,0–5,1</td>
									<td align="center">0,25</td>
									<td align="center">0,11–0,55</td>
								</tr>
								<tr>
									<td>Autopercepção de saúde</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">p &lt; 0,001 <sup>c</sup></td>
								</tr>
								<tr>
									<td>Muito boa</td>
									<td align="center">2,3</td>
									<td align="center">1,2–4,2</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Boa</td>
									<td align="center">6,8</td>
									<td align="center">5,6–8,2</td>
									<td align="center">2,98</td>
									<td align="center">1,59–5,66</td>
								</tr>
								<tr>
									<td>Regular</td>
									<td align="center">11,5</td>
									<td align="center">10,0–13,2</td>
									<td align="center">5,03</td>
									<td align="center">2,67–9,49</td>
								</tr>
								<tr>
									<td>Ruim/Muito ruim</td>
									<td align="center">23,0</td>
									<td align="center">17,9–29,0</td>
									<td align="center">10,0</td>
									<td align="center">5,16–19,50</td>
								</tr>
							</tbody>
						</table>
						<table-wrap-foot>
							<fn id="TFN2002">
								<p><sup>a</sup> Percentuais ajustados por pesos amostrais e por pós-estratificação, segundo idade e sexo. Foram mantidas no modelo ajustado somente as variáveis com valor de p &lt; 0,20.</p>
							</fn>
							<fn id="TFN3002">
								<p><sup>b</sup> p de heterogeneidade</p>
							</fn>
							<fn id="TFN4002">
								<p><sup>c</sup> p de tendência.</p>
							</fn>
							<fn id="TFN5002">
								<p><sup>d</sup> Considerando o n reduzido, as categorias “amarela” e “indígena” foram transformadas em <italic>missing</italic> para realização de modelo de regressão.</p>
							</fn>
						</table-wrap-foot>
					</table-wrap>
				</p>
				<p>Após análise ajustada, as variáveis que não permaneceram no modelo hierárquico foram classificação econômica, escolaridade, tabagismo e plano de saúde (p &gt; 0,20). A <xref ref-type="fig" rid="f03002">Figura 3</xref> demonstra as razões de prevalência ajustadas das variáveis mantidas no modelo hierárquico, dentre elas, somente cor da pele e situação conjugal não foram significativamente associadas à utilização de BZD na análise ajustada. A utilização de BZD foi cinco vezes maior em indivíduos com depressão, e aumentou conforme a piora da autopercepção de saúde. Indivíduos que relataram consumo abusivo de álcool apresentaram redução em 58% no risco de utilizarem BZD.</p>
				<p>
					<fig id="f03002">
						<label>Figura 3</label>
						<caption>
							<title>Razões de prevalência ajustadas para utilização de benzodiazepínicos em idosos brasileiros nos 15 dias anteriores à coleta dos dados da pesquisa. PNAUM, 2014 (n = 9.019).</title>
						</caption>
						<graphic xlink:href="1518-8787-rsp-56-10-gf03-pt.tif"/>
						<attrib><sup>a</sup> Considerando o n reduzido, as categorias “amarela” e “indígena” foram transformadas em missing para realização de modelo de regressão.</attrib>
					</fig>
				</p>
			</sec>
			<sec sec-type="discussion">
				<title>DISCUSSÃO</title>
				<p>Este é o primeiro estudo populacional com representatividade das cinco regiões brasileiras que avaliou a prevalência de utilização de BZD em idosos. A prevalência encontrada foi de 9,3%, superior à encontrada na Arábia Saudita (4%) <sup><xref ref-type="bibr" rid="B13">13</xref></sup> e inferior à relatada na França (31%) <sup><xref ref-type="bibr" rid="B14">14</xref></sup> , Finlândia (31%) <sup><xref ref-type="bibr" rid="B15">15</xref></sup> e Taiwan (43%) <sup><xref ref-type="bibr" rid="B16">16</xref></sup> . Em termos absolutos, entretanto, corresponde a um total de mais de dois milhões de idosos no país, representando um grande impacto em termos de saúde pública.</p>
				<p>Os fármacos mais frequentemente utilizados foram clonazepam e diazepam, medicamentos entre os BZD que são fornecidos gratuitamente pelo Sistema Único de Saúde (SUS) <sup><xref ref-type="bibr" rid="B17">17</xref></sup> . A maioria dos estudos brasileiros encontrou padrão semelhante <sup><xref ref-type="bibr" rid="B18">18</xref></sup> , somente uma pesquisa encontrou maior consumo de alprazolam e bromazepam <sup><xref ref-type="bibr" rid="B2">2</xref></sup> , observado na maioria dos países de alta renda onde tende-se a optar por medicamentos mais novos, com meia vida curta. Este estudo, porém, utilizou apenas informações oriundas de farmácias particulares <sup><xref ref-type="bibr" rid="B2">2</xref></sup> .</p>
				<p>Após análise ajustada, apresentaram maior prevalência de uso as mulheres, os indivíduos com idade entre 70 e 79 anos, os que apresentavam depressão ou multimorbidade, os que relataram ao menos uma visita à emergência ou internação hospitalar nos últimos 12 meses, os que utilizavam polifarmácia e os que relataram autopercepção de saúde ruim ou muito ruim. Por outro lado, apresentaram menor prevalência de utilização os residentes na Região Norte e os indivíduos que relataram consumo abusivo de álcool no último mês.</p>
				<p>O presente estudo apresenta algumas desvantagens, condizentes com o crescente aumento de perdas e recusas observadas nos inquéritos populacionais <sup><xref ref-type="bibr" rid="B10">10</xref></sup> . Dados de caracterização da amostra já publicados mostram taxas de resposta do domicílio de 51,7% e 51,5% para homens e mulheres, respectivamente, proporção subestimada, pois incluiu os domicílios vagos no cálculo. Foi encontrada ainda correlação negativa fraca porém estatisticamente significativa entre a renda média do setor censitário e a taxa de resposta em todas as regiões do país <sup><xref ref-type="bibr" rid="B10">10</xref></sup> . Outros estudos que avaliaram idosos, entretanto, não encontraram associação estatisticamente significativa entre nível socioeconômico e utilização de BZD <sup><xref ref-type="bibr" rid="B3">3</xref></sup> , reduzindo a possibilidade de ocorrência de viés de seleção. As taxas de resposta dos moradores foram semelhantes entre homens e mulheres (90,1% e 93,7%, respectivamente) <sup><xref ref-type="bibr" rid="B10">10</xref></sup> .</p>
				<p>Em relação ao sexo do entrevistado, mulheres apresentaram probabilidade cerca de duas vezes maior do que homens de utilizarem BZD, achado consistente na literatura <sup><xref ref-type="bibr" rid="B19">19</xref></sup> . Algumas questões são pautadas para explicar essa diferença: em primeiro lugar, estudos mostram que mulheres apresentam mais transtornos depressivos e ansiosos, enquanto homens apresentam com maior frequência transtornos aditivos e externalizantes <sup><xref ref-type="bibr" rid="B3">3</xref></sup> . Uma vez que os BZD são utilizados especialmente no tratamento dos primeiros, sua utilização pode ser um <italic>proxy</italic> para as diferenças de gênero na prevalência de transtornos mentais <sup><xref ref-type="bibr" rid="B20">20</xref></sup> , fortemente impactadas pelo grau de desigualdade de gênero dentro de uma sociedade patriarcal. Outra questão relevante é que as mulheres buscam mais os serviços de saúde para tratamento de problemas de saúde mental <sup><xref ref-type="bibr" rid="B3">3</xref> , <xref ref-type="bibr" rid="B20">20</xref></sup> . No contexto dos indivíduos idosos, esse achado tem particular relevância clínica, considerando o risco aumentado de quedas com uso de BZD e o risco elevado de fraturas em mulheres idosas, especialmente fraturas de quadril, que ocorrem com elevada morbimortalidade <sup><xref ref-type="bibr" rid="B21">21</xref></sup> .</p>
				<p>Foram detectadas amplas diferenças regionais, sendo a prevalência de utilização de BZD na Região Norte (1,8%) muito inferior à encontrada nas demais regiões. Estudos realizados no Brasil que avaliaram a utilização de BZD na população geral encontraram padrão semelhante <sup><xref ref-type="bibr" rid="B2">2</xref></sup> , com aumento do consumo nas cidades de maior densidade demográfica e maior percentual de médicos <sup><xref ref-type="bibr" rid="B2">2</xref></sup> . Fatores como trânsito caótico, sensação de insegurança, ambiente competitivo, grande apelo consumista e baixa coesão social compõe o estilo de vida das grandes cidades atuais, comprometem o bem-estar de seus habitantes e podem contribuir para a maior utilização de BZD observada nesses locais <sup><xref ref-type="bibr" rid="B2">2</xref></sup> . É importante considerar também que a venda dos BZD é controlada no Brasil desde 1998 <sup><xref ref-type="bibr" rid="B1">1</xref></sup> , de modo que o acesso à prescrição médica constitui um determinante para sua utilização. Assim, é provável que esse acesso seja dificultado nas regiões que contam com menor número de médicos por habitante: enquanto o país tem razão média de 2,27 médicos por mil habitantes, a Região Norte tem taxa de 1,30, 43% menor que a razão média nacional <sup><xref ref-type="bibr" rid="B22">22</xref></sup> .</p>
				<p>O diagnóstico prévio de depressão foi a variável independente mais importante para predizer a utilização de BZD em idosos. Indivíduos com história de depressão apresentaram prevalência de utilização de 39,9% e, mesmo após análise ajustada, apresentaram risco cinco vezes maior de utilizarem BZD em relação aos indivíduos sem diagnóstico de depressão. Achados semelhantes foram encontrados em outros estudos que avaliaram a utilização de BZD na população geral e em idosos <sup><xref ref-type="bibr" rid="B23">23</xref></sup> .</p>
				<p>Os medicamentos antidepressivos (AD) constituem tratamento de escolha para depressão e são eficazes também para o tratamento de sintomas ansiosos coexistentes. No entanto, os efeitos benéficos dos AD geralmente só são obtidos após várias semanas, período em que os BZD costumam ser prescritos visando um alívio mais imediato dos sintomas <sup><xref ref-type="bibr" rid="B24">24</xref></sup> . O benefício do tratamento combinado, entretanto, não se sustenta por mais de quatro semanas <sup><xref ref-type="bibr" rid="B25">25</xref></sup> . Ainda assim, a prevalência de utilização de BZD por tempo prolongado em idosos é elevada <sup><xref ref-type="bibr" rid="B24">24</xref></sup> . Estudos qualitativos apontam como possível causa, a renovação de prescrições iniciadas por outros médicos, buscando atender às solicitações dos pacientes e evitar prejuízo na relação médico-paciente <sup><xref ref-type="bibr" rid="B26">26</xref></sup> . É importante ressaltar que a dependência aos BZD ocorre dentro de poucas semanas de uso regular e está associada à síndrome de abstinência, caracterizada pela ocorrência de distúrbios do sono, ansiedade e agorafobia após a interrupção do uso, especialmente quando realizada abruptamente; a intensidade dos sintomas pode explicar as recaídas após tentativas de interrupção, resultando na perpetuação do uso <sup><xref ref-type="bibr" rid="B27">27</xref></sup> .</p>
				<p>Multimorbidade e polifarmácia apresentaram aumento de 1,4 e 1,3 vezes, respectivamente, na probabilidade de utilizar BZD, achado que reflete maior carga de doença e maior risco de transtornos de ansiedade <sup><xref ref-type="bibr" rid="B19">19</xref></sup> . Ambas as condições são mais prevalentes em idosos e encontram-se associadas a maior risco de iatrogenia, piora funcional, perda da independência e autonomia <sup><xref ref-type="bibr" rid="B8">8</xref></sup> . Usuários de um maior número de medicamentos apresentam ainda risco elevado de interações medicamentosas e eventos adversos como confusão, agitação e delirium. Esses sintomas podem ser confundidos com ansiedade e levar à prescrição de BZD, agravando o quadro <sup><xref ref-type="bibr" rid="B19">19</xref></sup> .</p>
				<p>Indivíduos que relataram consumo abusivo de álcool no último mês apresentaram redução na probabilidade de utilização de BZD (RP = 0,42; IC95% 0,19–0,94). A maioria dos estudos que avaliaram consumo de álcool no último mês encontram achados semelhantes <sup><xref ref-type="bibr" rid="B14">14</xref> , <xref ref-type="bibr" rid="B18">18</xref> , <xref ref-type="bibr" rid="B19">19</xref></sup> . Sabe-se que o álcool e os BZD compartilham mecanismos de ação comuns <sup><xref ref-type="bibr" rid="B3">3</xref></sup> e potencialmente produzem efeitos comparáveis na ansiedade e no sono basais, levando os indivíduos a sentirem a necessidade de um ou outro, mas não de ambos <sup><xref ref-type="bibr" rid="B19">19</xref></sup> . Essa escolha parece ser influenciada, ao menos em parte, pelo sexo do indivíduo, de modo que o presente estudo encontrou maior prevalência de utilização de BZD nas mulheres e de álcool nos homens. É possível ainda que essa diferença resulte de um menor número de prescrições de BZD entre usuários de álcool, uma vez que o efeito das duas substâncias como depressoras do centro respiratório é sinérgico, podendo resultar em intoxicações graves e potencialmente fatais <sup><xref ref-type="bibr" rid="B18">18</xref></sup> .</p>
				<p>Somente um estudo encontrou associação oposta, com abuso de álcool determinando maior utilização de BZD (OR 3,1–IC95% 1,7–5,7) <sup><xref ref-type="bibr" rid="B3">3</xref></sup> . Esse estudo, porém, incluiu a população geral e utilizou um período recordatório de 12 meses, tanto para abuso de álcool quanto para utilização de BZD. Em análise de mediação, os autores notaram que o efeito do álcool sobre utilização de BZD foi tanto direto quanto indireto, passando por sintomas depressivos, inatividade física e distúrbios do sono. Pauta-se ainda que, por apresentarem mecanismos de ação comuns, álcool e BZD poderiam levar à tolerância cruzada. Assim, indivíduos dependentes de BZD podem optar por usar álcool durante os períodos de privação, da mesma forma que a classe dos BZD faz parte do tratamento para síndrome de abstinência do álcool <sup><xref ref-type="bibr" rid="B3">3</xref></sup> . Esse fenômeno poderia justificar também os achados encontrados neste estudo, que avaliou o uso de álcool como determinante mais proximal no modelo hierárquico. Assim, é necessária uma abordagem integrada para o tratamento de ambas as condições.</p>
				<p>Visita à emergência ou internação hospitalar nos últimos 12 meses também foi associada a uma maior prescrição de BZD para idosos, com aumento do risco em 1,4 vezes. Estudos recentes demostraram elevada prevalência de idosos recebendo BZD durante a hospitalização, o que é preocupante, visto que novas prescrições de BZD fornecidas a pacientes idosos na alta hospitalar podem levar ao uso crônico do medicamento <sup><xref ref-type="bibr" rid="B28">28</xref></sup> .</p>
				<p>Por isso, é importante ressaltar que a prevalência de utilização de BZD sem receita encontrada na literatura varia de 3,3% a 8,4% <sup><xref ref-type="bibr" rid="B2">2</xref></sup> , demonstrando que esforços que visam aumentar a fiscalização sobre a venda do medicamento não são suficientes para resolver o problema, uma vez que a maioria dos usuários obtém o fármaco por meio de prescrição médica. Assim, o uso racional de BZD parte da valorização da educação médica continuada e do estímulo às parcerias multiprofissionais <sup><xref ref-type="bibr" rid="B2">2</xref> , <xref ref-type="bibr" rid="B9">9</xref></sup> , pautadas no atendimento integral ao paciente idoso, com o objetivo de reduzir os eventos adversos evitáveis, e maximizar a independência e autonomia desses indivíduos <sup><xref ref-type="bibr" rid="B8">8</xref></sup> .</p>
				<p>A relevância do tema requer investigação adicional, especialmente no contexto de pós-pandemia de covid-19 <sup><xref ref-type="bibr" rid="B29">29</xref></sup> . Evidências emergentes demonstram impactos dramáticos na saúde mental dos indivíduos, com aumento da ansiedade e do isolamento social devido às políticas de distanciamento físico introduzidas para controle da infecção <sup><xref ref-type="bibr" rid="B30">30</xref></sup> , afetando particularmente os idosos. É provável que a prevalência de utilização de BZD, já elevada, aumente ainda mais nesse contexto, de modo que, uma vez controlada a emergência de saúde pública relacionada à pandemia em si, se fazem necessárias políticas públicas que promovam o uso racional dessa classe de medicamentos.</p>
				<p>Apesar das potenciais limitações inerentes a um estudo transversal, especialmente em relação à inferência causal, o presente estudo trouxe dados consistentes e com representatividade nacional, até o momento inexplorados na literatura. A despeito das recomendações contrárias ao uso <sup><xref ref-type="bibr" rid="B6">6</xref></sup> , os resultados revelaram elevada prevalência de utilização de BZD em indivíduos idosos, particularmente naqueles que apresentam quadro de depressão, além de amplas diferenças em relação à região do país e ao sexo do indivíduo.</p>
			</sec>
		</body>
		<back>
			<ack>
				<title>Agradecimentos</title>
				<p>Ao Ministério da Saúde, pela encomenda, financiamento e apoio técnico para a realização da Pesquisa Nacional sobre Acesso, Utilização e Promoção do Uso Racional de Medicamentos, e ao Thiago Melo, pela colaboração na elaboração do material gráfico.</p>
			</ack>
			<fn-group>
				<fn fn-type="financial-disclosure" id="fn2002">
					<p><bold>Financiamento:</bold> Ministério da Saúde por meio da Secretaria de Ciência e Tecnologia Insumos Estratégicos – SCTIE (Processo 25000.111834/2).</p>
				</fn>
			</fn-group>
		</back>
	</sub-article>
</article>